58 results on '"Srivastava IK"'
Search Results
2. Stabilization of HIV-1 envelope int the CD4-bound conformation through specific cross linking of a CD4 mimetic
- Author
-
Martin, G., Burke, B., Thai, R., Dey, Ak, Combes, O., Heyd, B., Geonnotti, Ar, Montefiori, Dc, Kan, E., Lian, Y., Sun, Yd, Abache, T., Ulmer, Jb, Madaoui, H., Guerois, R., Barnett, Sw, Srivastava, Ik, Kessler, P., Martin, L., Franche-Comté Électronique Mécanique, Thermique et Optique - Sciences et Technologies (UMR 6174) (FEMTO-ST), Université de Technologie de Belfort-Montbeliard (UTBM)-Ecole Nationale Supérieure de Mécanique et des Microtechniques (ENSMM)-Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Système membranaires, photobiologie, stress et détoxication (SMPSD), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS), Université de Technologie de Belfort-Montbeliard (UTBM)-Ecole Nationale Supérieure de Mécanique et des Microtechniques (ENSMM)-Université de Franche-Comté (UFC), and Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre National de la Recherche Scientifique (CNRS)
- Subjects
[SDV.BBM.BM]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Molecular biology - Published
- 2011
3. Glycobiotechnology of the Insect Cell-Baculovirus Expression System Technology.
- Author
-
Palomares LA, Srivastava IK, Ramírez OT, and Cox MMJ
- Subjects
- Animals, Cattle, Glycosylation, Recombinant Proteins genetics, Technology, Baculoviridae genetics, Baculoviridae metabolism, Insecta metabolism
- Abstract
The insect cell-baculovirus expression system technology (BEST) has a prominent role in producing recombinant proteins to be used as research and diagnostic reagents and vaccines. The glycosylation profile of proteins produced by the BEST is composed predominantly of terminal mannose glycans, and, in Trichoplusia ni cell lines, core α3 fucosylation, a profile different to that in mammals. Insects contain all the enzymatic activities needed for complex N- and O-glycosylation and sialylation, although few reports of complex glycosylation and sialylation by the BEST exist. The insect cell line and culture conditions determine the glycosylation profile of proteins produced by the BEST. The promoter used, dissolved oxygen tension, presence of sugar precursors, bovine serum or hemolymph, temperature, and the time of harvest all influence glycosylation, although more research is needed. The lack of activity of glycosylation enzymes possibly results from the transcription regulation and stress imposed by baculovirus infection. To solve this limitation, the glycosylation pathway of insect cells has been engineered to produce complex sialylated glycans and to eliminate α3 fucosylation, either by generating transgenic cell lines or by using baculovirus vectors. These strategies have been successful. Complex glycosylation, sialylation, and inhibition of α3 fucosylation have been achieved, although the majority of glycans still have terminal mannose residues. The implication of insect glycosylation in the proteins produced by the BEST is discussed. Graphical Abstract., (© 2018. Springer International Publishing AG, part of Springer Nature.)
- Published
- 2021
- Full Text
- View/download PDF
4. Improved stability of recombinant hemagglutinin using a formulation containing sodium thioglycolate.
- Author
-
Rhodes DG, Holtz K, Robinson P, Wang K, McPherson CE, Cox MM, and Srivastava IK
- Subjects
- Animals, Antibodies, Viral blood, Dynamic Light Scattering, Electrophoresis, Polyacrylamide Gel, Hemagglutinins genetics, Immunodiffusion, Influenza Vaccines administration & dosage, Influenza Vaccines genetics, Influenza Vaccines immunology, Mice, Inbred BALB C, Recombinant Proteins chemistry, Recombinant Proteins genetics, Recombinant Proteins immunology, Hemagglutinins chemistry, Hemagglutinins immunology, Influenza Vaccines chemistry, Thioglycolates chemistry, Vaccine Potency
- Abstract
This study was designed to improve the stability of liquid formulations of recombinant influenza hemagglutinin (rHA) and to understand the mechanism of early loss of potency for rHA. The potency of rHA derived from several influenza strains was determined using single radial immunodiffusion (SRID), and the structure of the rHA was characterized using SDS-PAGE and dynamic light scattering. rHA formed disulfide cross-linked multimers, and potency decreased during extended storage. To reduce disulfide-mediated cross-linking and early potency loss, rHA was formulated with sodium thioglycolate (STG) and citrate. Addition of 80 mM STG and 55 mM sodium citrate inhibited disulfide-mediated cross-linking without affecting protein function for each rHA tested. The shelf life of the rHA formulation with STG-citrate, based on potency as determined by SRID, was extended as much as 20-fold, compared to a control formulation without STG-citrate. STG-citrate did not have a significant effect on the immunogenicity of H1 A/California/7/2009 rHA in mice., (Copyright © 2015 Elsevier Ltd. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
5. Dissolved carbon dioxide determines the productivity of a recombinant hemagglutinin component of an influenza vaccine produced by insect cells.
- Author
-
Meghrous J, Khramtsov N, Buckland BC, Cox MM, Palomares LA, and Srivastava IK
- Subjects
- Animals, Bioreactors, Cell Line, Hemagglutinin Glycoproteins, Influenza Virus genetics, Hydrogen-Ion Concentration, Influenza Vaccines genetics, Insecta, Recombinant Proteins genetics, Recombinant Proteins metabolism, Vaccines, Synthetic genetics, Vaccines, Synthetic metabolism, Carbon Dioxide analysis, Culture Media chemistry, Hemagglutinin Glycoproteins, Influenza Virus metabolism, Influenza Vaccines metabolism
- Abstract
Dissolved carbon dioxide (dCO2 ) accumulation during cell culture has been recognized as an important parameter that needs to be controlled for successful scale-up of animal cell culture because above a certain concentration there are adverse effects on cell growth performance and protein production. We investigated the effect of accumulation of dCO2 in bioreactor cultures of expresSF+(®) insect cells infected with recombinant baculoviruses expressing recombinant influenza virus hemagglutinins (rHA). Different strategies for bioreactor cultures were used to obtain various ranges of concentrations of dCO2 (<50, 50-100, 100-200, and >200 mmHg) and to determine their effects on recombinant protein production and cell metabolic activity. We show that the accumulation of dCO2 at levels > 100 mmHg resulted in reduced metabolic activity, slowed cell growth, prolonged culture viability after infection, and decreased infection kinetics. The reduced rHA yields were not caused by the decrease in the extracellular pH that resulted from dCO2 accumulation, but were most likely due to the effect of dCO2 accumulation in cells. The results obtained here at the 2 L scale have been used for the design of large-scale processes to manufacture the rHA based recombinant vaccine Flublok™ at the 2500 L scale Biotechnol. Bioeng. 2015;112: 2267-2275. © 2015 Wiley Periodicals, Inc., (© 2015 Wiley Periodicals, Inc.)
- Published
- 2015
- Full Text
- View/download PDF
6. Immunogens Modeling a Fusion-Intermediate Conformation of gp41 Elicit Antibodies to the Membrane Proximal External Region of the HIV Envelope Glycoprotein.
- Author
-
Vassell R, He Y, Vennakalanti P, Dey AK, Zhuang M, Wang W, Sun Y, Biron-Sorek Z, Srivastava IK, LaBranche CC, Montefiori DC, Barnett SW, and Weiss CD
- Subjects
- Animals, Antibodies, Monoclonal immunology, Enzyme-Linked Immunosorbent Assay, Neutralization Tests, Protein Conformation, Rabbits, AIDS Vaccines immunology, HIV Antibodies immunology, HIV Envelope Protein gp41 immunology, HIV-1 immunology, Vaccines, Synthetic immunology, Viral Fusion Proteins immunology
- Abstract
The membrane proximal external region (MPER) of the gp41 subunit of the HIV-1 envelope glycoprotein (Env) contains determinants for broadly neutralizing antibodies and has remained an important focus of vaccine design. However, creating an immunogen that elicits broadly neutralizing antibodies to this region has proven difficult in part due to the relative inaccessibility of the MPER in the native conformation of Env. Here, we describe the antigenicity and immunogenicity of a panel of oligomeric gp41 immunogens designed to model a fusion-intermediate conformation of Env in order to enhance MPER exposure in a relevant conformation. The immunogens contain segments of the gp41 N- and C-heptad repeats to mimic a trapped intermediate, followed by the MPER, with variations that include different N-heptad lengths, insertion of extra epitopes, and varying C-termini. These well-characterized immunogens were evaluated in two different immunization protocols involving gp41 and gp140 proteins, gp41 and gp160 DNA primes, and different immunization schedules and adjuvants. We found that the immunogens designed to reduce extension of helical structure into the MPER elicited the highest MPER antibody binding titers, but these antibodies lacked neutralizing activity. The gp41 protein immunogens also elicited higher MPER titers than the gp140 protein immunogen. In prime-boost studies, the best MPER responses were seen in the groups that received DNA priming with gp41 vectors followed by gp41 protein boosts. Finally, although titers to the entire protein immunogen were similar in the two immunization protocols, MPER-specific titers differed, suggesting that the immunization route, schedule, dose, or adjuvant may differentially influence MPER immunogenicity. These findings inform the design of future MPER immunogens and immunization protocols.
- Published
- 2015
- Full Text
- View/download PDF
7. Modifications of cysteine residues in the transmembrane and cytoplasmic domains of a recombinant hemagglutinin protein prevent cross-linked multimer formation and potency loss.
- Author
-
Holtz KM, Robinson PS, Matthews EE, Hashimoto Y, McPherson CE, Khramtsov N, Reifler MJ, Meghrous J, Rhodes DG, Cox MM, and Srivastava IK
- Subjects
- Animals, Cysteine genetics, Cysteine immunology, Hemagglutinin Glycoproteins, Influenza Virus genetics, Humans, Influenza A virus chemistry, Influenza A virus genetics, Influenza Vaccines genetics, Influenza, Human immunology, Influenza, Human prevention & control, Mice, Mice, Inbred BALB C, Protein Structure, Tertiary, Recombinant Proteins chemistry, Recombinant Proteins genetics, Recombinant Proteins immunology, Cysteine chemistry, Hemagglutinin Glycoproteins, Influenza Virus chemistry, Hemagglutinin Glycoproteins, Influenza Virus immunology, Influenza A virus immunology, Influenza Vaccines chemistry, Influenza Vaccines immunology, Influenza, Human virology
- Abstract
Background: Recombinant hemagglutinin (rHA) is the active component in Flublok®; a trivalent influenza vaccine produced using the baculovirus expression vector system (BEVS). HA is a membrane bound homotrimer in the influenza virus envelope, and the purified rHA protein assembles into higher order rosette structures in the final formulation of the vaccine. During purification and storage of the rHA, disulfide mediated cross-linking of the trimers within the rosette occurs and results in reduced potency. Potency is measured by the Single Radial Immuno-diffusion (SRID) assay to determine the amount of HA that has the correct antigenic form., Results: The five cysteine residues in the transmembrane (TM) and cytoplasmic (CT) domains of the rHA protein from the H3 A/Perth/16/2009 human influenza strain have been substituted to alanine and/or serine residues to produce three different site directed variants (SDVs). These SDVs have been evaluated to determine the impact of the TM and CT cysteines on potency, cross-linking, and the biochemical and biophysical properties of the rHA. Modification of these cysteine residues prevents disulfide bond cross-linking in the TM and CT, and the resulting rHA maintains potency for at least 12 months at 25 °C. The strategy of substituting TM and CT cysteines to prevent potency loss has been successfully applied to another H3 rHA protein (from the A/Texas/50/2012 influenza strain) further demonstrating the utility of the approach., Conclusion: rHA potency can be maintained by preventing non-specific disulfide bonding and cross-linked multimer formation. Substitution of carboxy terminal cysteines is an alternative to using reducing agents, and permits room temperature storage of the vaccine.
- Published
- 2014
- Full Text
- View/download PDF
8. Trimeric HIV Env provides epitope occlusion mediated by hypervariable loops.
- Author
-
Moscoso CG, Xing L, Hui J, Hu J, Kalkhoran MB, Yenigun OM, Sun Y, Paavolainen L, Martin L, Vahlne A, Zambonelli C, Barnett SW, Srivastava IK, and Cheng RH
- Subjects
- CD4 Antigens chemistry, CD4 Antigens metabolism, Epitopes genetics, HIV Envelope Protein gp120 chemistry, HIV Envelope Protein gp120 genetics, HIV Envelope Protein gp120 metabolism, HIV Envelope Protein gp41 chemistry, HIV Envelope Protein gp41 genetics, HIV Envelope Protein gp41 metabolism, Humans, Models, Molecular, Peptide Fragments genetics, Protein Binding, Protein Conformation, Protein Interaction Domains and Motifs, Sequence Deletion, env Gene Products, Human Immunodeficiency Virus genetics, env Gene Products, Human Immunodeficiency Virus metabolism, Epitopes chemistry, Peptide Fragments chemistry, Protein Multimerization, env Gene Products, Human Immunodeficiency Virus chemistry
- Abstract
Hypervariable loops of HIV-1 Env protein gp120 are speculated to play roles in the conformational transition of Env to the receptor binding-induced metastable state. Structural analysis of full-length Env-based immunogens, containing the entire V2 loop, displayed tighter association between gp120 subunits, resulting in a smaller trimeric diameter than constructs lacking V2. A prominent basal quaternary location of V2 and V3' that challenges previous reports would facilitate gp41-independent gp120-gp120 interactions and suggests a quaternary mechanism of epitope occlusion facilitated by hypervariable loops. Deletion of V2 resulted in dramatic exposure of basal, membrane-proximal gp41 epitopes, consistent with its predicted basal location. The structural features of HIV-1 Env characterized here provide grounds for a paradigm shift in loop exposure and epitope occlusion, while providing substantive rationale for epitope display required for elicitation of broadly neutralizing antibodies, as well as substantiating previous pertinent literature disregarded in recent reports.
- Published
- 2014
- Full Text
- View/download PDF
9. Mechanism of a decrease in potency for the recombinant influenza A virus hemagglutinin H3 antigen during storage.
- Author
-
Hickey JM, Holtz KM, Manikwar P, Joshi SB, McPherson CE, Buckland B, Srivastava IK, Middaugh CR, and Volkin DB
- Subjects
- Chemical Phenomena, Cysteine analysis, Cysteine chemistry, Cystine analysis, Cystine chemistry, Drug Stability, Drug Storage, Excipients chemistry, Hemagglutinin Glycoproteins, Influenza Virus genetics, Hemagglutinin Glycoproteins, Influenza Virus metabolism, Hemagglutinin Glycoproteins, Influenza Virus pharmacology, Hydrodynamics, Immunodiffusion, Influenza A Virus, H3N2 Subtype drug effects, Influenza A Virus, H3N2 Subtype growth & development, Influenza A Virus, H3N2 Subtype immunology, Influenza Vaccines genetics, Influenza Vaccines metabolism, Influenza Vaccines pharmacology, Octoxynol chemistry, Oxidation-Reduction, Peptide Mapping, Protein Stability, Protein Structure, Secondary, Recombinant Proteins chemistry, Recombinant Proteins genetics, Recombinant Proteins metabolism, Recombinant Proteins pharmacology, Spectroscopy, Fourier Transform Infrared, Temperature, Thioglycolates chemistry, Hemagglutinin Glycoproteins, Influenza Virus chemistry, Influenza A Virus, H3N2 Subtype metabolism, Influenza Vaccines chemistry
- Abstract
The recombinant hemagglutinin (rHA)-based influenza vaccine Flublok® has recently been approved in the United States as an alternative to the traditional egg-derived flu vaccines. Flublok is a purified vaccine with a hemagglutinin content that is threefold higher than standard inactivated influenza vaccines. When rHA derived from an H3N2 influenza virus was expressed, purified, and stored for 1 month, a rapid loss of in vitro potency (∼50%) was observed as measured by the single radial immunodiffusion (SRID) assay. A comprehensive characterization of the rHA protein antigen was pursued to identify the potential causes and mechanisms of this potency loss. In addition, the biophysical and chemical stability of the rHA in different formulations and storage conditions was evaluated over time. Results demonstrate that the potency loss over time did not correlate with trends in changes to the higher order structure or hydrodynamic size of the rHA. The most likely mechanism for the early loss of potency was disulfide-mediated cross-linking of rHA, as the formation of non-native disulfide-linked multimers over time correlated well with the observed potency loss. Furthermore, a loss of free thiol content, particularly in specific cysteine residues in the antigen's C-terminus, was correlated with potency loss measured by SRID., (© 2014 Wiley Periodicals, Inc. and the American Pharmacists Association.)
- Published
- 2014
- Full Text
- View/download PDF
10. Development of a stable virus-like particle vaccine formulation against Chikungunya virus and investigation of the effects of polyanions.
- Author
-
Kramer RM, Zeng Y, Sahni N, Kueltzo LA, Schwartz RM, Srivastava IK, Crane L, Joshi SB, Volkin DB, and Middaugh CR
- Subjects
- Alphavirus Infections prevention & control, Alphavirus Infections virology, Animals, Chikungunya Fever, Circular Dichroism, Light, Osmolar Concentration, Particle Size, Polyelectrolytes, Protein Stability, Scattering, Radiation, Chikungunya virus chemistry, Excipients chemistry, Polymers chemistry, Vaccines, Virus-Like Particle chemistry
- Abstract
Chikungunya virus (CHIKV) is an alphavirus that infects millions of people every year, especially in the developing world. The selective expression of recombinant CHIKV capsid and envelope proteins results in the formation of self-assembled virus-like particles (VLPs) that have been shown to protect nonhuman primates against infection from multiple strains of CHIKV. This study describes the characterization, excipient screening, and optimization of CHIKV VLP solution conditions toward the development of a stable parenteral formulation. The CHIKV VLPs were found to be poorly soluble at pH 6 and below. Circular dichroism, intrinsic fluorescence, and static and dynamic light scattering measurements were therefore performed at neutral pH, and results consistent with the formation of molten globule structures were observed at elevated temperatures. A library of generally recognized as safe excipients was screened for their ability to physically stabilize CHIKV VLPs using a high-throughput turbidity-based assay. Sugars, sugar alcohols, and polyanions were identified as potential stabilizers and the concentrations and combinations of select excipients were optimized. The effects of polyanions were further studied, and while all polyanions tested stabilized CHIKV VLPs against aggregation, the effects of polyanions on conformational stability varied., (© 2013 Wiley Periodicals, Inc. and the American Pharmacists Association.)
- Published
- 2013
- Full Text
- View/download PDF
11. Stabilizing exposure of conserved epitopes by structure guided insertion of disulfide bond in HIV-1 envelope glycoprotein.
- Author
-
Kassa A, Dey AK, Sarkar P, Labranche C, Go EP, Clark DF, Sun Y, Nandi A, Hartog K, Desaire H, Montefiori D, Carfi A, Srivastava IK, and Barnett SW
- Subjects
- Animals, Antibodies metabolism, Binding Sites, CD4 Antigens chemistry, CD4 Antigens genetics, Epitopes chemistry, Epitopes genetics, Female, HIV Envelope Protein gp120 administration & dosage, HIV Envelope Protein gp120 genetics, HIV Envelope Protein gp120 immunology, HIV-1 chemistry, HIV-1 genetics, HIV-1 immunology, Humans, Immunization, Ligands, Models, Molecular, Mutation, Protein Binding, Protein Interaction Domains and Motifs, Rabbits, Surface Plasmon Resonance, env Gene Products, Human Immunodeficiency Virus administration & dosage, env Gene Products, Human Immunodeficiency Virus genetics, env Gene Products, Human Immunodeficiency Virus immunology, CD4 Antigens immunology, Disulfides chemistry, Epitopes immunology, HIV Envelope Protein gp120 chemistry, env Gene Products, Human Immunodeficiency Virus chemistry
- Abstract
Entry of HIV-1 into target cells requires binding of the viral envelope glycoprotein (Env) to cellular receptors and subsequent conformational changes that culminates in fusion of viral and target cell membranes. Recent structural information has revealed that these conformational transitions are regulated by three conserved but potentially flexible layers stacked between the receptor-binding domain (gp120) and the fusion arm (gp41) of Env. We hypothesized that artificial insertion of a covalent bond will 'snap' Env into a conformation that is less mobile and stably expose conserved sites. Therefore, we analyzed the interface between these gp120 layers (layers 1, 2 and 3) and identified residues that may form disulfide bonds when substituted with cysteines. We subsequently probed the structures of the resultant mutant gp120 proteins by assaying their binding to a variety of ligands using Surface Plasmon Resonance (SPR) assay. We found that a single disulfide bond strategically inserted between the highly conserved layers 1 and 2 (C65-C115) is able to 'lock' gp120 in a CD4 receptor bound conformation (in the absence of CD4), as indicated by the lower dissociation constant (Kd) for the CD4-induced (CD4i) epitope binding 17b antibody. When disulfide-stabilized monomeric (gp120) and trimeric (gp140) Envs were used to immunize rabbits, they were found to elicit a higher proportion of antibodies directed against both CD4i and CD4 binding site epitopes than the wild-type proteins. These results demonstrate that structure-guided stabilization of inter-layer interactions within HIV-1 Env can be used to expose conserved epitopes and potentially overcome the sequence diversity of these molecules.
- Published
- 2013
- Full Text
- View/download PDF
12. Putative role of Tat-Env interaction in HIV infection.
- Author
-
Poon S, Moscoso CG, Xing L, Kan E, Sun Y, Kolatkar PR, Vahlne AG, Srivastava IK, Barnett SW, and Cheng RH
- Subjects
- Cryoelectron Microscopy, HIV Envelope Protein gp120 chemistry, HIV-1 chemistry, Humans, Protein Binding, Virus Replication, tat Gene Products, Human Immunodeficiency Virus chemistry, HIV Envelope Protein gp120 metabolism, HIV Infections metabolism, HIV-1 metabolism, tat Gene Products, Human Immunodeficiency Virus metabolism
- Abstract
Objective: To study the complex formed between Tat protein and Env soluble trimeric immunogen, and compare with previously determined structures of Env native trimers and Env-CD4m complexes., Design: The soluble Env trimer was used to mimic the spike glycoprotein on the virus surface for the study. To overcome limitations of other structural determination methods, cryoelectron microscopy was employed to image the complex, and single particle reconstruction was utilized to reconstruct the structure of the complex from collected micrographs. Molecular modeling of gp120-Tat was performed to provide atomic coordinates for docking., Methods: Images were preprocessed by multivariate statistical analysis to identify principal components of variation then submitted for reconstruction. Reconstructed structures were docked with modeled gp120-Tat atomic coordinates to study the positions of crucial epitopes., Results: Analysis of the Env-Tat complex demonstrated an intermediate structure between Env native trimers and Env-CD4m structures. Docking results indicate that the CD4-binding site and the V3 loop are exposed in the Env-Tat complex. The integrin-binding sequence in Tat was also exposed in Env-Tat docking., Conclusion: The intermediate structure induced by Tat-interaction with Env could potentially provide an explanation for increased virus infection in the presence of Tat protein. Consequently, exposure of CD4-binding sites and a putative integrin-binding sequence on Tat in the complex may provide a new avenue for rational design of an effective HIV vaccine., (© 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins)
- Published
- 2013
- Full Text
- View/download PDF
13. Use of a polyanionic carbomer, Carbopol971P, in combination with MF59, improves antibody responses to HIV-1 envelope glycoprotein.
- Author
-
Dey AK, Burke B, Sun Y, Hartog K, Heeney JL, Montefiori D, Srivastava IK, and Barnett SW
- Subjects
- AIDS Vaccines administration & dosage, AIDS Vaccines adverse effects, Acrylates adverse effects, Acrylates metabolism, Adjuvants, Immunologic adverse effects, Animals, Antibodies, Neutralizing immunology, Female, HIV Antibodies immunology, Humans, Hydrogen-Ion Concentration, Polysorbates adverse effects, Protein Binding, Protein Stability, Rabbits, Squalene adverse effects, env Gene Products, Human Immunodeficiency Virus metabolism, AIDS Vaccines immunology, Acrylates administration & dosage, Adjuvants, Immunologic administration & dosage, HIV Antibodies blood, HIV-1 immunology, Polysorbates administration & dosage, Squalene administration & dosage, env Gene Products, Human Immunodeficiency Virus immunology
- Abstract
Identification of optimal antigen(s) and adjuvant combination(s) to elicit potent, protective, and long-lasting immunity has been a major challenge for the development of effective vaccines against chronic viral pathogens, such as HIV-1, for which there are not yet any licensed vaccines. Here we describe the use of a novel adjuvant approach employing Carbopol 971P(®) NF (hereafter referred to as Carbopol971P), a cross-linked polyanionic carbomer, in combination with the Novartis proprietary oil-in-water adjuvant, MF59, as a potentially safe and effective adjuvant to augment humoral immune responses to the HIV-1 envelope glycoprotein (Env). Intramuscular immunization of small animals with recombinant Env glycoprotein (gp140) formulated in Carbopol971P plus MF59 gave significantly higher titers of binding and virus neutralizing antibodies as compared to immunization using gp140 with either MF59 or Carbopol971P alone. In addition, the antibodies generated were of higher avidity. Importantly, the use of Carbopol971P plus MF59 did not cause any serious adverse reactions or any obvious health problems in animals upon intramuscular administration. Hence, the Carbopol971P plus MF59 adjuvant formulation may provide a benefit for future vaccine applications., (Copyright © 2012 Elsevier Ltd. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
14. Mixed adjuvant formulations reveal a new combination that elicit antibody response comparable to Freund's adjuvants.
- Author
-
Lai RP, Seaman MS, Tonks P, Wegmann F, Seilly DJ, Frost SD, LaBranche CC, Montefiori DC, Dey AK, Srivastava IK, Sattentau Q, Barnett SW, and Heeney JL
- Subjects
- AIDS Vaccines immunology, Acrylic Resins, Animals, Antibodies, Neutralizing immunology, Antibody Formation drug effects, Epitopes immunology, Freund's Adjuvant pharmacology, HIV Infections immunology, HIV-1 immunology, Humans, Rabbits, env Gene Products, Human Immunodeficiency Virus genetics, env Gene Products, Human Immunodeficiency Virus immunology, Adjuvants, Immunologic pharmacology, Antibodies, Neutralizing drug effects, Antibody Formation immunology, Polysorbates administration & dosage, Polyvinyls administration & dosage, Squalene administration & dosage
- Abstract
Adjuvant formulations capable of inducing high titer and high affinity antibody responses would provide a major advance in the development of vaccines to viral infections such as HIV-1. Although oil-in-water emulsions, such as Freund's adjuvant (FCA/FIA), are known to be potent, their toxicity and reactogenicity make them unacceptable for human use. Here, we explored different adjuvants and compared their ability to elicit antibody responses to FCA/FIA. Recombinant soluble trimeric HIV-1 gp140 antigen was formulated in different adjuvants, including FCA/FIA, Carbopol-971P, Carbopol-974P and the licensed adjuvant MF59, or combinations of MF59 and Carbopol. The antigen-adjuvant formulation was administered in a prime-boost regimen into rabbits, and elicitation of antigen binding and neutralizing antibodies (nAbs) was evaluated. When used individually, only FCA/FIA elicited significantly higher titer of nAbs than the control group (gp140 in PBS (p<0.05)). Sequential prime-boost immunizations with different adjuvants did not offer improvements over the use of FCA/FIA or MF59. Remarkably however, the concurrent use of the combination of Carbopol-971P and MF59 induced potent adjuvant activity with significantly higher titer nAbs than FCA/FIA (p<0.05). This combination was not associated with any obvious local or systemic adverse effects. Antibody competition indicated that the majority of the neutralizing activities were directed to the CD4 binding site (CD4bs). Increased antibody titers to the gp41 membrane proximal external region (MPER) and gp120 V3 were detected when the more potent adjuvants were used. These data reveal that the combination of Carbopol-971P and MF59 is unusually potent for eliciting nAbs to a variety of HIV-1 nAb epitopes.
- Published
- 2012
- Full Text
- View/download PDF
15. Elicitation of neutralizing antibodies directed against CD4-induced epitope(s) using a CD4 mimetic cross-linked to a HIV-1 envelope glycoprotein.
- Author
-
Dey AK, Burke B, Sun Y, Sirokman K, Nandi A, Hartog K, Lian Y, Geonnotti AR, Montefiori D, Franti M, Martin G, Carfi A, Kessler P, Martin L, Srivastava IK, and Barnett SW
- Subjects
- AIDS Vaccines chemical synthesis, AIDS Vaccines immunology, Animals, Biomimetics, Cross-Linking Reagents pharmacology, Epitopes immunology, Female, HIV Antibodies metabolism, Immunization, Neutralization Tests, Rabbits, Recombinant Proteins chemical synthesis, Recombinant Proteins pharmacology, env Gene Products, Human Immunodeficiency Virus chemistry, env Gene Products, Human Immunodeficiency Virus metabolism, Antibodies, Neutralizing metabolism, Antibody Formation drug effects, CD4 Antigens immunology, HIV-1 immunology, Recombinant Proteins immunology, env Gene Products, Human Immunodeficiency Virus immunology
- Abstract
The identification of HIV-1 envelope glycoprotein (Env) structures that can generate broadly neutralizing antibodies (BNAbs) is pivotal to the development of a successful vaccine against HIV-1 aimed at eliciting effective humoral immune responses. To that end, the production of novel Env structure(s) that might induce BNAbs by presentation of conserved epitopes, which are otherwise occluded, is critical. Here, we focus on a structure that stabilizes Env in a conformation representative of its primary (CD4) receptor-bound state, thereby exposing highly conserved "CD4 induced" (CD4i) epitope(s) known to be important for co-receptor binding and subsequent virus infection. A CD4-mimetic miniprotein, miniCD4 (M64U1-SH), was produced and covalently complexed to recombinant, trimeric gp140 envelope glycoprotein (gp140) using site-specific disulfide linkages. The resulting gp140-miniCD4 (gp140-S-S-M64U1) complex was recognized by CD4i antibodies and the HIV-1 co-receptor, CCR5. The gp140-miniCD4 complex elicited the highest titers of CD4i binding antibodies as well as enhanced neutralizing antibodies against Tier 1 viruses as compared to gp140 protein alone following immunization of rabbits. Neutralization against HIV-2(7312/V434M) and additional serum mapping confirm the specific elicitation of antibodies directed to the CD4i epitope(s). These results demonstrate the utility of structure-based approach in improving immunogenic response against specific region, such as the CD4i epitope(s) here, and its potential role in vaccine application.
- Published
- 2012
- Full Text
- View/download PDF
16. HIV-1 tat promotes integrin-mediated HIV transmission to dendritic cells by binding Env spikes and competes neutralization by anti-HIV antibodies.
- Author
-
Monini P, Cafaro A, Srivastava IK, Moretti S, Sharma VA, Andreini C, Chiozzini C, Ferrantelli F, Cossut MR, Tripiciano A, Nappi F, Longo O, Bellino S, Picconi O, Fanales-Belasio E, Borsetti A, Toschi E, Schiavoni I, Bacigalupo I, Kan E, Sernicola L, Maggiorella MT, Montin K, Porcu M, Leone P, Leone P, Collacchi B, Palladino C, Ridolfi B, Falchi M, Macchia I, Ulmer JB, Buttò S, Sgadari C, Magnani M, Federico MP, Titti F, Banci L, Dallocchio F, Rappuoli R, Ensoli F, Barnett SW, Garaci E, and Ensoli B
- Subjects
- AIDS Vaccines administration & dosage, AIDS Vaccines immunology, Animals, Antibodies, Neutralizing immunology, Antibodies, Neutralizing metabolism, Binding Sites, Dendritic Cells immunology, HIV Antibodies immunology, HIV Envelope Protein gp120 immunology, HIV Envelope Protein gp120 metabolism, HIV Infections immunology, HIV Infections prevention & control, HIV Infections transmission, HIV Infections virology, HIV-1 immunology, Humans, Integrins immunology, Macaca fascicularis, Male, Molecular Docking Simulation, Neutralization Tests, Oligopeptides metabolism, Protein Binding, Protein Interaction Domains and Motifs immunology, Receptors, CCR5 metabolism, Receptors, CXCR4 metabolism, Recombinant Proteins immunology, Recombinant Proteins isolation & purification, Recombinant Proteins metabolism, T-Lymphocytes immunology, T-Lymphocytes metabolism, T-Lymphocytes virology, Vaccines, Virus-Like Particle administration & dosage, Vaccines, Virus-Like Particle immunology, Virus Internalization, Virus Replication, env Gene Products, Human Immunodeficiency Virus chemistry, env Gene Products, Human Immunodeficiency Virus immunology, tat Gene Products, Human Immunodeficiency Virus chemistry, tat Gene Products, Human Immunodeficiency Virus immunology, Dendritic Cells virology, HIV Antibodies metabolism, HIV-1 metabolism, Integrins metabolism, env Gene Products, Human Immunodeficiency Virus metabolism, tat Gene Products, Human Immunodeficiency Virus metabolism
- Abstract
Use of Env in HIV vaccine development has been disappointing. Here we show that, in the presence of a biologically active Tat subunit vaccine, a trimeric Env protein prevents in monkeys virus spread from the portal of entry to regional lymph nodes. This appears to be due to specific interactions between Tat and Env spikes that form a novel virus entry complex favoring R5 or X4 virus entry and productive infection of dendritic cells (DCs) via an integrin-mediated pathway. These Tat effects do not require Tat-transactivation activity and are blocked by anti-integrin antibodies (Abs). Productive DC infection promoted by Tat is associated with a highly efficient virus transmission to T cells. In the Tat/Env complex the cysteine-rich region of Tat engages the Env V3 loop, whereas the Tat RGD sequence remains free and directs the virus to integrins present on DCs. V2 loop deletion, which unshields the CCR5 binding region of Env, increases Tat/Env complex stability. Of note, binding of Tat to Env abolishes neutralization of Env entry or infection of DCs by anti-HIV sera lacking anti-Tat Abs, which are seldom present in natural infection. This is reversed, and neutralization further enhanced, by HIV sera containing anti-Tat Abs such as those from asymptomatic or Tat-vaccinated patients, or by sera from the Tat/Env vaccinated monkeys. Thus, both anti-Tat and anti-Env Abs are required for efficient HIV neutralization. These data suggest that the Tat/Env interaction increases HIV acquisition and spreading, as a mechanism evolved by the virus to escape anti-Env neutralizing Abs. This may explain the low effectiveness of Env-based vaccines, which are also unlikely to elicit Abs against new Env epitopes exposed by the Tat/Env interaction. As Tat also binds Envs from different clades, new vaccine strategies should exploit the Tat/Env interaction for both preventative and therapeutic interventions.
- Published
- 2012
- Full Text
- View/download PDF
17. Stabilization of HIV-1 envelope in the CD4-bound conformation through specific cross-linking of a CD4 mimetic.
- Author
-
Martin G, Burke B, Thaï R, Dey AK, Combes O, Ramos OH, Heyd B, Geonnotti AR, Montefiori DC, Kan E, Lian Y, Sun Y, Abache T, Ulmer JB, Madaoui H, Guérois R, Barnett SW, Srivastava IK, Kessler P, and Martin L
- Subjects
- Animals, Antigen Presentation, CHO Cells, Cricetinae, Cricetulus, Cross-Linking Reagents chemistry, Cysteine chemistry, Disulfides, Protein Binding, Protein Conformation, Receptors, CCR5 chemistry, CD4-Positive T-Lymphocytes virology, HIV Envelope Protein gp120 chemistry, HIV-1 chemistry, Viral Envelope Proteins chemistry
- Abstract
CD4 binding on gp120 leads to the exposure of highly conserved regions recognized by the HIV co-receptor CCR5 and by CD4-induced (CD4i) antibodies. A covalent gp120-CD4 complex was shown to elicit CD4i antibody responses in monkeys, which was correlated with control of the HIV virus infection (DeVico, A., Fouts, T., Lewis, G. K., Gallo, R. C., Godfrey, K., Charurat, M., Harris, I., Galmin, L., and Pal, R. (2007) Proc. Natl. Acad. Sci. U.S.A. 104, 17477-17482). Because the inclusion of CD4 in a vaccine formulation should be avoided, due to potential autoimmune reactions, we engineered small sized CD4 mimetics (miniCD4s) that are poorly immunogenic and do not induce anti-CD4 antibodies. We made covalent complexes between such an engineered miniCD4 and gp120 or gp140, through a site-directed coupling reaction. These complexes were recognized by CD4i antibodies as well as by the HIV co-receptor CCR5. In addition, they elicit CD4i antibody responses in rabbits and therefore represent potential vaccine candidates that mimic an important HIV fusion intermediate, without autoimmune hazard.
- Published
- 2011
- Full Text
- View/download PDF
18. A combination HIV vaccine based on Tat and Env proteins was immunogenic and protected macaques from mucosal SHIV challenge in a pilot study.
- Author
-
Ferrantelli F, Maggiorella MT, Schiavoni I, Sernicola L, Olivieri E, Farcomeni S, Pavone-Cossut MR, Moretti S, Belli R, Collacchi B, Srivastava IK, Titti F, Cafaro A, Barnett SW, and Ensoli B
- Subjects
- AIDS Vaccines genetics, Adjuvants, Immunologic administration & dosage, Animals, Antibodies, Neutralizing blood, Antibody Formation, Epitope Mapping, HIV Antibodies blood, HIV Infections immunology, Immunity, Cellular, Macaca fascicularis, Male, Pilot Projects, RNA, Viral blood, AIDS Vaccines immunology, HIV Infections prevention & control, env Gene Products, Human Immunodeficiency Virus immunology, tat Gene Products, Human Immunodeficiency Virus immunology
- Abstract
HIV native Tat and V2 loop-deleted Env (EnvΔV2) proteins already proved safe and immunogenic in phase I clinical testing as single vaccine components. Further, a phase II vaccine trial with Tat showed intensification of the therapeutic effects of HAART in successfully treated HIV-infected individuals. Here a pilot study assessed the immunogenicity and protective efficacy of an HIV/AIDS vaccine based on the combination of Tat and EnvΔV2 proteins in cynomolgus macaques against homologous intrarectal challenge with 35 MID(50) (monkey infectious dose 50) of an R5 simian-human immunodeficiency virus (SHIV(SF162P4cy)). Upon challenge, three of four macaques immunized with Tat and EnvΔV2, and two of three monkeys immunized with EnvΔV2 alone were protected from infection. In contrast, all three control animals, which had been either administered with the adjuvants only or left untreated, and an additional monkey immunized with Tat alone became systemically infected. Protection of the macaques vaccinated with EnvΔV2 or Tat/EnvΔV2 correlated with higher peak titers of pre-challenge neutralizing antibodies obtained during the immunization period (between 70 and 3 weeks before challenge) and with anti-Env V3 loop binding antibodies assessed 3 weeks before challenge. Compared to EnvΔV2 alone, the Tat and EnvΔV2 combined vaccine elicited faster antibody responses (IgM) with a trend, early in the vaccination schedule, after the second immunization including EnvΔV2, towards broader anti-Env IgG epitope specificity and a higher ratio of neutralizing to Env-binding antibody titers. As the number of immunizations increased, vaccination with EnvΔV2 approached the immune response assessed after two inocula with the Tat/EnvΔV2 combined vaccine, even though some differences remained between groups, as indicated by anti-Env IgG epitope mapping. In fact, three weeks before challenge, plasma IgG of animals in the EnvΔV2 group showed a trend towards stronger specificity for the V1 loop and V5 loop-C5 regions of Env, whereas the Tat/EnvΔV2 group displayed an overall higher reactivity for epitopes within the Env V3 loop throughout the immunization period. Although differences in terms of protection rate were not found between the EnvΔV2 or Tat/EnvΔV2 vaccination groups in this pilot study, vaccination with Tat/EnvΔV2 appeared to accelerate the induction of potentially protective antibody responses to Env. In particular, antibodies to the Env V3 loop, whose levels at pre-challenge correlated with protection, were already higher early in the vaccination schedule in monkeys immunized with Tat/EnvΔV2 as compared to EnvΔV2 alone. Further studies including larger vaccination groups and fewer immunizations with these two vaccine candidates are needed to confirm these findings and to assess whether the Tat/EnvΔV2 vaccine may afford superior protection against infection., (Copyright © 2011 Elsevier Ltd. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
19. Novel adjuvants and delivery systems for enhancing immune responses induced by immunogens.
- Author
-
Dey AK and Srivastava IK
- Subjects
- Humans, Immunization methods, Adjuvants, Immunologic pharmacology, Antigens immunology, Drug Delivery Systems, Vaccines immunology
- Abstract
Vaccines are the most important preventive measure against infectious diseases. In developing an effective vaccine, besides the primary challenge of identifying the most relevant immunogen and efficient regime of immunization, selection of a potent adjuvant and delivery method is equally critical. The formulation of immunogens with different adjuvants may affect the affinity maturation of antibody responses differently, suggesting that the structure of specific epitopes within the immunogen may be influenced by different adjuvants. Thus, developing adjuvants that can efficiently activate both the innate and adaptive arms of the immune system is a major challenge for vaccine researchers. The use of novel adjuvants in combination with novel immunogen design holds great promise towards the goal of enhancing the potency, breadth and durability of vaccines. This article summarizes the different immunopotentiator (and immunomodulators) as well as the delivery systems that are available for vaccine generation and the types of immune responses that each of them induces. Also discussed are adjuvants that have a combination of both immunomodualtory and delivery properties.
- Published
- 2011
- Full Text
- View/download PDF
20. Structural evidence of glycoprotein assembly in cellular membrane compartments prior to Alphavirus budding.
- Author
-
Soonsawad P, Xing L, Milla E, Espinoza JM, Kawano M, Marko M, Hsieh C, Furukawa H, Kawasaki M, Weerachatyanukul W, Srivastava R, Barnett SW, Srivastava IK, and Cheng RH
- Subjects
- Animals, Biological Transport, Cell Line, Cricetinae, Electron Microscope Tomography, Vacuoles, Viral Proteins metabolism, Alphavirus physiology, Cell Membrane virology, Glycoproteins metabolism, Virus Assembly, Virus Release
- Abstract
Membrane glycoproteins of alphavirus play a critical role in the assembly and budding of progeny virions. However, knowledge regarding transport of viral glycoproteins to the plasma membrane is obscure. In this study, we investigated the role of cytopathic vacuole type II (CPV-II) through in situ electron tomography of alphavirus-infected cells. The results revealed that CPV-II contains viral glycoproteins arranged in helical tubular arrays resembling the basic organization of glycoprotein trimers on the envelope of the mature virions. The location of CPV-II adjacent to the site of viral budding suggests a model for the transport of structural components to the site of budding. Thus, the structural characteristics of CPV-II can be used in evaluating the design of a packaging cell line for replicon production.
- Published
- 2010
- Full Text
- View/download PDF
21. Antibody-mediated protection against mucosal simian-human immunodeficiency virus challenge of macaques immunized with alphavirus replicon particles and boosted with trimeric envelope glycoprotein in MF59 adjuvant.
- Author
-
Barnett SW, Burke B, Sun Y, Kan E, Legg H, Lian Y, Bost K, Zhou F, Goodsell A, Zur Megede J, Polo J, Donnelly J, Ulmer J, Otten GR, Miller CJ, Vajdy M, and Srivastava IK
- Subjects
- AIDS Vaccines administration & dosage, AIDS Vaccines immunology, Adjuvants, Immunologic administration & dosage, Alphavirus genetics, Animals, Antibodies, Viral blood, Cell Line, Disease Models, Animal, HIV Infections immunology, HIV Infections virology, HIV-1 genetics, HIV-1 immunology, Humans, Immunization, Macaca, Male, Polysorbates administration & dosage, Replicon, Simian Immunodeficiency Virus genetics, Squalene administration & dosage, Squalene immunology, env Gene Products, Human Immunodeficiency Virus administration & dosage, env Gene Products, Human Immunodeficiency Virus genetics, Alphavirus immunology, Antibodies, Viral immunology, HIV Infections prevention & control, Simian Immunodeficiency Virus immunology, env Gene Products, Human Immunodeficiency Virus immunology
- Abstract
We have previously shown that rhesus macaques were partially protected against high-dose intravenous challenge with simian-human immunodeficiency virus SHIV(SF162P4) following sequential immunization with alphavirus replicon particles (VRP) of a chimeric recombinant VEE/SIN alphavirus (derived from Venezuelan equine encephalitis virus [VEE] and the Sindbis virus [SIN]) encoding human immunodeficiency virus type 1 HIV-1(SF162) gp140DeltaV2 envelope (Env) and trimeric Env protein in MF59 adjuvant (R. Xu, I. K. Srivastava, C. E. Greer, I. Zarkikh, Z. Kraft, L. Kuller, J. M. Polo, S. W. Barnett, and L. Stamatatos, AIDS Res. Hum. Retroviruses 22:1022-1030, 2006). The protection did not require T-cell immune responses directed toward simian immunodeficiency virus (SIV) Gag. We extend those findings here to demonstrate antibody-mediated protection against mucosal challenge in macaques using prime-boost regimens incorporating both intramuscular and mucosal routes of delivery. The macaques in the vaccination groups were primed with VRP and then boosted with Env protein in MF59 adjuvant, or they were given VRP intramuscular immunizations alone and then challenged with SHIV(SF162P4) (intrarectal challenge). The results demonstrated that these vaccines were able to effectively protect the macaques to different degrees against subsequent mucosal SHIV challenge, but most noteworthy, all macaques that received the intramuscular VRP prime plus Env protein boost were completely protected. A statistically significant association was observed between the titer of virus neutralizing and binding antibodies as well as the avidity of anti-Env antibodies measured prechallenge and protection from infection. These results highlight the merit of the alphavirus replicon vector prime plus Env protein boost vaccine approach for the induction of protective antibody responses and are of particular relevance to advancing our understanding of the potential correlates of immune protection against HIV infection at a relevant mucosal portal of entry.
- Published
- 2010
- Full Text
- View/download PDF
22. Neutralizing antibody responses to subtype B and C adjuvanted HIV envelope protein vaccination in rabbits.
- Author
-
Burke B, Gómez-Román VR, Lian Y, Sun Y, Kan E, Ulmer J, Srivastava IK, and Barnett SW
- Subjects
- Adjuvants, Immunologic, Animals, Antibody Formation immunology, Drug Evaluation, Preclinical, HIV Infections prevention & control, Neutralization Tests, Oligodeoxyribonucleotides immunology, Polysorbates, Rabbits, Squalene immunology, Vaccination, env Gene Products, Human Immunodeficiency Virus genetics, AIDS Vaccines immunology, Antibodies, Viral immunology, HIV Infections immunology, HIV-1 immunology, env Gene Products, Human Immunodeficiency Virus immunology
- Abstract
Improving the potency, breadth, and durability of neutralizing antibody responses to HIV are major challenges for HIV vaccine development. To address these challenges, the studies described evaluate in rabbits the titers, breadth, and epitope specificities of antibody responses elicited by HIV envelope subunit vaccines adjuvanted with MF59 with or without CpG oligodeoxynucleotide (ODN). Animals were immunized with trimeric o-gp140DeltaV2 derived from subtype B HIV-1(SF162) or subtype C HIV-1(TV1), or proteins from both strains. Immunization with SF162 or TV1 with MF59/CpG elicited higher titers of binding and neutralizing antibodies to SF162 than monovalent immunization with MF59 alone (P<0.01). Bivalent immunization increased binding and neutralizing antibody titers over single envelope immunization in MF59 (P<0.01). Bivalent immunization also improved neutralization breadth. Epitope mapping indicated neutralizing activity in rabbits was directed to V3 and V4. Overall, our data suggests that a multivalent vaccination approach with MF59 and CpG can enhance humoral responses to HIV-1.
- Published
- 2009
- Full Text
- View/download PDF
23. A simple one-step method for the preparation of HIV-1 envelope glycoprotein immunogens based on a CD4 mimic peptide.
- Author
-
Martin G, Sun Y, Heyd B, Combes O, Ulmer JB, Descours A, Barnett SW, Srivastava IK, and Martin L
- Subjects
- Animals, CHO Cells, Cricetinae, Cricetulus, HIV Antibodies metabolism, HIV Envelope Protein gp120 immunology, Peptides chemistry, Protein Binding, Protein Multimerization, Rats, Rats, Wistar, Recombinant Proteins metabolism, CD4 Antigens metabolism, Chromatography, Affinity methods, HIV Envelope Protein gp120 isolation & purification, HIV-1, Receptors, CCR5 metabolism
- Abstract
To counteract the problems associated with the purification of HIV envelope, we developed a new purification method exploiting the high affinity of a peptide mimicking CD4 towards the viral glycoprotein. This miniCD4 was used as a ligand in affinity chromatography and allowed the separation in one step of HIV envelope monomer from cell supernatant and the capture of pre-purified trimer. This simple and robust method of purification yielded to active and intact HIV envelopes as proved by the binding of CCR5 HIV co-receptor, CD4 and a panel of well-characterized monoclonal antibodies. The immunogenicity of miniCD4-purified HIV envelope was further assessed in rats. The analysis of the humoral response indicated that elicited antibodies were able to recognize a broad range of HIV envelopes. Finally, this method based on a chemically synthesized peptide may represent a convenient and versatile tool for protein purification compatible far scale-up in both academic and pharmaceutical researches.
- Published
- 2008
- Full Text
- View/download PDF
24. Comparative evaluation of trimeric envelope glycoproteins derived from subtype C and B HIV-1 R5 isolates.
- Author
-
Srivastava IK, Kan E, Sun Y, Sharma VA, Cisto J, Burke B, Lian Y, Hilt S, Biron Z, Hartog K, Stamatatos L, Diaz-Avalos R, Cheng RH, Ulmer JB, and Barnett SW
- Subjects
- Animals, Antibodies, Monoclonal, Antibodies, Viral, CD4 Antigens metabolism, CHO Cells, Cell Line, Cricetinae, Cricetulus, Epitopes, Gene Expression Regulation, Viral, Gene Products, env chemistry, Gene Products, env genetics, Genetic Variation, HIV Antigens, Humans, Protein Binding, Gene Products, env metabolism, HIV-1 classification, HIV-1 metabolism
- Abstract
We previously reported that an envelope (Env) glycoprotein immunogen (o-gp140DeltaV2SF162) containing a partial deletion in the second variable loop (V2) derived from the R5-tropic HIV-1 isolate SF162 partially protected vaccinated rhesus macaques against pathogenic SHIV(SF162P4) virus. Extending our studies to subtype C isolate TV1, we have purified o-gp140DeltaV2TV1 (subtype C DeltaV2 trimer) to homogeneity, performed glycosylation analysis, and determined its ability to bind CD4, as well as a panel of well-characterized neutralizing monoclonal antibodies (mAb). In general, critical epitopes are preserved on the subtype C DeltaV2 trimer; however, we did not observe significant binding for the b12 mAb. The molecular mass of subtype C DeltaV2 trimer was found to be 450 kDa, and the hydrodynamic radius was found to be 10.87 nm. Our data suggest that subtype C DeltaV2 trimer binds to CD4 with an affinity comparable to o-gp140DeltaV2SF162 (subtype B DeltaV2 trimer). Using isothermal titration calorimetric (ITC) analysis, we demonstrated that all three CD4 binding sites (CD4-BS) in both subtype C and B trimers are exposed and accessible. However, compared to subtype B trimer, the three CD4-BS in subtype C trimer have different affinities for CD4, suggesting a cooperativity of CD4 binding in subtype C trimer but not in subtype B trimer. Negative staining electron microscopy of the subtype C DeltaV2 trimer has demonstrated that it is in fact a trimer. These results highlight the importance of studying subtype C Env, and also of developing appropriate subtype C-specific reagents that may be used for better immunological characterization of subtype C Env for developing an AIDS vaccine.
- Published
- 2008
- Full Text
- View/download PDF
25. Characterization of immune responses elicited in mice by intranasal co-immunization with HIV-1 Tat, gp140 DeltaV2Env and/or SIV Gag proteins and the nontoxicogenic heat-labile Escherichia coli enterotoxin.
- Author
-
Caputo A, Brocca-Cofano E, Castaldello A, Voltan R, Gavioli R, Srivastava IK, Barnett SW, Cafaro A, and Ensoli B
- Subjects
- AIDS Vaccines administration & dosage, Administration, Intranasal, Animals, Bacterial Toxins administration & dosage, Enterotoxins administration & dosage, Escherichia coli Proteins administration & dosage, Female, Gene Products, tat immunology, Glycoproteins genetics, HIV Antibodies biosynthesis, HIV Infections immunology, HIV Infections prevention & control, HIV-1 immunology, Humans, Immunity, Mucosal, Mice, Mice, Inbred BALB C, Simian Immunodeficiency Virus metabolism, T-Lymphocytes immunology, Vaccination, AIDS Vaccines immunology, Adjuvants, Immunologic administration & dosage, Bacterial Toxins immunology, Enterotoxins immunology, Escherichia coli Proteins immunology, Gene Products, gag immunology, Glycoproteins immunology, Simian Immunodeficiency Virus immunology
- Abstract
The development of a vaccine against HIV/AIDS capable of inducing broad humoral and cellular responses at both systemic and mucosal sites, able to stop or reduce viral infection at the portal of entry, represents the only realistic way to control the infection caused by HIV world-wide. The promising results obtained with the HIV-1 Tat-based vaccines in preclinical and clinical settings, the evidence that a broad immunity against HIV correlates with reduced viral load or virus control, as well as the availability of novel gp140 V2-loop deleted HIV-1 Env (DeltaV2Env) immunogens capable of inducing cross-reactive neutralizing antibodies, have led to the design of new vaccine strategies based on the combination of non-structural and structural proteins. In this study, we demonstrate that immunization with a biologically active HIV-1 Tat protein in combination with the oligomeric HIV-1 gp140 DeltaV2Env and/or SIV Gag proteins, delivered intranasally with the detoxified LTK63 mucosal adjuvant, whose safety has been recently shown in humans, elicits long-lasting local and systemic antibody and cellular immune responses against the co-administered antigens in a fashion similar to immune responses induced by vaccination with Tat, DeltaV2Env and Gag proteins alone. The results indicate lack of antigen interference implying that HIV-1 Tat is an optimal co-antigen for combined vaccine strategies employing DeltaV2Env and/or Gag proteins.
- Published
- 2008
- Full Text
- View/download PDF
26. Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope.
- Author
-
Barnett SW, Srivastava IK, Kan E, Zhou F, Goodsell A, Cristillo AD, Ferrai MG, Weiss DE, Letvin NL, Montefiori D, Pal R, and Vajdy M
- Subjects
- AIDS Vaccines immunology, Administration, Intranasal, Animals, Antibodies, Viral analysis, Antibodies, Viral blood, CD4-Positive T-Lymphocytes immunology, Female, HIV Infections immunology, HIV Infections virology, HIV-1 immunology, Humans, Immunization, Injections, Intramuscular, Macaca mulatta, Simian Acquired Immunodeficiency Syndrome immunology, Simian Acquired Immunodeficiency Syndrome virology, Simian Immunodeficiency Virus immunology, env Gene Products, Human Immunodeficiency Virus immunology, AIDS Vaccines administration & dosage, HIV Infections prevention & control, HIV-1 pathogenicity, Simian Acquired Immunodeficiency Syndrome prevention & control, Simian Immunodeficiency Virus pathogenicity, Vagina virology, env Gene Products, Human Immunodeficiency Virus administration & dosage
- Abstract
Background: Worldwide, the majority of human immunodeficiency virus (HIV) infections occur by heterosexual transmission. Thus, the development of a vaccine that can prevent intravaginal HIV infection is an important goal of AIDS vaccine research., Objectives: To determine which single or combination of systemic and mucosal routes of immunizations of female rhesus macaques with an HIV-1 SF162 envelope protein vaccine induced protection against intravaginal challenge with SHIV., Design: Female rhesus macaques were immunized with an HIV-1 SF162 envelope protein vaccine administered systemically (intramuscularly), or mucosally (intranasally), or as a sequential combination of both routes. The macaques were then challenged intravaginally with SHIV SF162P4, expressing an envelope that is closely matched (homologous) to the vaccine., Results: Macaques receiving intramuscular immunizations, alone or in combination with intranasal immunizations, were protected from infection, with no detectable plasma viral RNA, provirus, or seroconversion to nonvaccine viral proteins, and better preservation of intestinal CD4+ T cells. Serum neutralizing antibodies against the challenge virus appeared to correlate with protection., Conclusions: The results of this study demonstrate that, in the nonhuman primate model, it is possible for vaccine-elicited immune responses to prevent infection after intravaginal administration of virus.
- Published
- 2008
- Full Text
- View/download PDF
27. Isolation and characterization of monoclonal antibodies elicited by trimeric HIV-1 Env gp140 protein immunogens.
- Author
-
Derby NR, Gray S, Wayner E, Campogan D, Vlahogiannis G, Kraft Z, Barnett SW, Srivastava IK, and Stamatatos L
- Subjects
- Amino Acid Sequence, Animals, Antibodies, Monoclonal isolation & purification, Antibodies, Viral isolation & purification, Cross Reactions, Epitope Mapping, Gene Products, env metabolism, Glycosylation, HIV Envelope Protein gp41 immunology, Mice, Molecular Sequence Data, Neutralization Tests, env Gene Products, Human Immunodeficiency Virus, Antibodies, Monoclonal immunology, Antibodies, Viral immunology, Gene Products, env immunology, HIV-1 immunology
- Abstract
Eleven anti-HIV Env monoclonal antibodies (MAbs) were isolated from mice immunized with soluble Env proteins derived from the clade B Env, SF162, or DeltaV2 (a derivative of SF162 lacking the V2 loop). All six anti-gp120 MAbs studied, neutralized SF162 and their activities were dependent by the glycosylation patterns of the V1, V2 or V3 loops. Only one anti-gp120 MAb (an anti-V3 MAb) displayed cross-neutralizing activity, which was influenced by the type of V1 loop present on the target heterologous viruses. None of the five anti-gp41 MAbs studied displayed anti-SF162 neutralizing activity. Our studies indicate that the current limitation of soluble HIV Env gp140 immunogens to elicit robust cross-reactive neutralizing antibody responses is not only due to the elicitation of high titers of homologous antibodies but also due to the elicitation of antibodies whose epitopes are naturally occluded, or not present, on the virion-associated Env.
- Published
- 2007
- Full Text
- View/download PDF
28. Candidate HIV-1 gp140DeltaV2, Gag and Tat vaccines protect against experimental HIV-1/MuLV challenge.
- Author
-
Bråve A, Hinkula J, Cafaro A, Eriksson LE, Srivastava IK, Magnani M, Ensoli B, Barnett SW, Wahren B, and Rollman E
- Subjects
- AIDS Vaccines genetics, AIDS Vaccines immunology, Adjuvants, Immunologic, Animals, Disease Models, Animal, Gene Products, gag genetics, Gene Products, tat genetics, HIV Antibodies blood, HIV Infections virology, Humans, Immunization, Immunization Schedule, Immunoglobulin G blood, Leukemia Virus, Murine, Mice, Mice, Inbred C57BL genetics, Mice, Transgenic, Polysorbates, Squalene, T-Lymphocytes immunology, env Gene Products, Human Immunodeficiency Virus genetics, AIDS Vaccines administration & dosage, Gene Products, gag immunology, Gene Products, tat immunology, HIV Infections prevention & control, HIV-1 pathogenicity, env Gene Products, Human Immunodeficiency Virus immunology
- Abstract
Pre-clinical HIV-1 vaccine protocols, using multiple vaccine modalities and a potent adjuvant were assessed for vaccine efficacy in an experimental HIV-1 challenge model. C57Bl/6 mice were immunized with DNA plasmids encoding HIV-1 gp140, Gag and Tat alone or in combination with the corresponding recombinant proteins formulated in the adjuvant MF59. HIV-1 DNA alone or a DNA prime protein boost schedule resulted in complete protection against challenge with HIV-1/MuLV-infected murine cells. Although HIV-1 protein immunization in combination with MF59 resulted in partial protection, the DNA priming seemed to be crucial for obtaining full protection against the challenge. It is likely that the partial protection seen after immunization with protein alone is, to a certain extent, due to effects of the adjuvant since some animals that received the adjuvant MF59 alone were protected from the challenge. For the most part, antigen-specific cell-mediated immune responses as detected in the spleen (in contrast to responses detected in peripheral blood) of immunized animals appeared to be associated with protection in this study.
- Published
- 2007
- Full Text
- View/download PDF
29. Direct inactivation of human immunodeficiency virus type 1 by a novel small-molecule entry inhibitor, DCM205.
- Author
-
Duong YT, Meadows DC, Srivastava IK, Gervay-Hague J, and North TW
- Subjects
- Acquired Immunodeficiency Syndrome prevention & control, Acquired Immunodeficiency Syndrome transmission, CD4 Antigens drug effects, Gene Products, env metabolism, HIV Envelope Protein gp120 chemistry, HIV Envelope Protein gp120 metabolism, HeLa Cells, Humans, Pyrogallol pharmacology, env Gene Products, Human Immunodeficiency Virus, Anti-HIV Agents pharmacology, Anti-Infective Agents, Local pharmacology, HIV-1 drug effects, Pyrogallol analogs & derivatives, Sulfones pharmacology
- Abstract
With more than 40 million people living with human immunodeficiency virus (HIV), there is an urgent need to develop drugs that can be used in the form of a topical microbicide to prevent infection through sexual transmission. DCM205 is a recently discovered small-molecule inhibitor of HIV type 1 (HIV-1) that is able to directly inactivate HIV-1 in the absence of a cellular target. DCM205 is active against CXCR4-, CCR5-, and dual-tropic laboratory-adapted and primary strains of HIV-1. DCM205 binds to the HIV-1 envelope glycoprotein, and competition studies map the DCM205 binding at or near the V3 loop of gp120. Binding to this site interferes with the soluble CD4 interaction. With its ability to disable the virus particle, DCM205 represents a promising new class of HIV entry inhibitor that can be used as a strategy in the prevention of HIV-1/AIDS.
- Published
- 2007
- Full Text
- View/download PDF
30. Viral evolution in macaques coinfected with CCR5- and CXCR4-tropic SHIVs in the presence or absence of vaccine-elicited anti-CCR5 SHIV neutralizing antibodies.
- Author
-
Burke B, Derby NR, Kraft Z, Saunders CJ, Dai C, Llewellyn N, Zharkikh I, Vojtech L, Zhu T, Srivastava IK, Barnett SW, and Stamatatos L
- Subjects
- AIDS Vaccines administration & dosage, AIDS Vaccines immunology, Amino Acid Sequence, Amino Acid Substitution genetics, Animals, CD4 Lymphocyte Count, Disease Models, Animal, HIV Envelope Protein gp120 genetics, HIV Envelope Protein gp120 immunology, HIV-1 genetics, Macaca mulatta, Molecular Sequence Data, Mutation, Neutralization Tests, RNA, Viral blood, Receptors, CCR5 immunology, Receptors, CCR5 physiology, Recombination, Genetic, Selection, Genetic, Simian Immunodeficiency Virus genetics, Simian Immunodeficiency Virus immunology, Simian Immunodeficiency Virus physiology, Viral Load, Adaptation, Biological, Evolution, Molecular, HIV Antibodies blood, HIV Infections immunology, HIV Infections virology, HIV-1 immunology, HIV-1 physiology
- Abstract
Macaques were immunized with SF162 Env-based gp140 immunogens and challenged simultaneously with the CCR5-tropic homologous SHIV(SF162P4) and the CXCR4-tropic heterologous SHIV(SF33A) viruses. Both mock-immunized and immunized animals became dually infected. Prior immunization preferentially reduced the viral replication of the homologous virus during primary infection but the relative replication of the two coinfecting viruses during chronic infection was unaffected by prior immunization, despite the fact that five of six immunized animals maintained a significantly lower overall viral replication that the control animals. Neutralizing antibodies participated in controlling the replication of SHIV(SF162P4), but not that of SHIV(SF33A). Dual infection resulted in the emergence and predominance within the circulating CCR5 virus pool, of a variant with a distinct neutralization phenotype. The signature of this variant was the presence of three amino acid changes in gp120, two of which were located in the receptor and coreceptor binding sites. Also, a significant fraction of the viruses circulating in the blood, as early as two weeks post-infection, was recombinants and prior immunization did not prevent their emergence. These findings provide new insights into the dynamic interaction of CCR5- and CXCR4-tropic HIV isolates that are potentially relevant in better understanding HIV-mediated pathogenesis.
- Published
- 2006
- Full Text
- View/download PDF
31. Characterization of immune responses elicited in macaques immunized sequentially with chimeric VEE/SIN alphavirus replicon particles expressing SIVGag and/or HIVEnv and with recombinant HIVgp140Env protein.
- Author
-
Xu R, Srivastava IK, Greer CE, Zarkikh I, Kraft Z, Kuller L, Polo JM, Barnett SW, and Stamatatos L
- Subjects
- Animals, Encephalitis Virus, Venezuelan Equine genetics, Genetic Vectors, Macaca mulatta, Recombinant Proteins immunology, Sindbis Virus, Vaccines, Synthetic immunology, env Gene Products, Human Immunodeficiency Virus, AIDS Vaccines immunology, Antibodies, Viral biosynthesis, Gene Products, env immunology, Gene Products, gag immunology, HIV Antibodies biosynthesis, Replicon
- Abstract
In the present study, macaques were coimmunized with VEErep/SINenv chimeric alphavirus replicon particles expressing SIVp55Gag and HIVDeltaV2gp140Env or only with replicon particles expressing HIVDeltaV2gp140Env. All animals were subsequently immunized with recombinant trimeric HIVDeltaV2gp140Env protein. During alphavirus immunization, anti-SIVGag and anti-HIVEnv-specific interferon (IFN)-gamma responses, as well as high titers of anti-HIVEnv binding (gp120 but not gp41 specific) and anti-HIV neutralizing antibodies, were generated. The subsequent immunization with recombinant HIVDeltaV2gp140 enhanced the neutralizing antibody titers and Env-specific IFN-gamma responses. Following intravenous challenge with the R5- tropic SHIV(SF162P4) virus, significantly lower primary plasma viremia levels were recorded in the immunized animals, as compared to control animals immunized with replicon particles expressing influenza virus HA. Our results show that this method of immunization elicits both strong cellular immunity and neutralizing antibodies in primates and, thus, merits further investigation.
- Published
- 2006
- Full Text
- View/download PDF
32. Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterologous HIV-1 infection.
- Author
-
Derby NR, Kraft Z, Kan E, Crooks ET, Barnett SW, Srivastava IK, Binley JM, and Stamatatos L
- Subjects
- AIDS Vaccines administration & dosage, AIDS Vaccines immunology, Animals, Gene Products, env genetics, HIV Infections immunology, HIV Infections prevention & control, HIV Infections virology, Humans, Immune Sera immunology, Immunization, Macaca mulatta, Neutralization Tests, SAIDS Vaccines administration & dosage, SAIDS Vaccines immunology, Simian Acquired Immunodeficiency Syndrome, env Gene Products, Human Immunodeficiency Virus, Antibodies, Viral blood, Gene Products, env immunology, HIV Antibodies blood, HIV-1 immunology, Simian Immunodeficiency Virus immunology
- Abstract
The antibody responses elicited in rhesus macaques immunized with soluble human immunodeficiency virus (HIV) Env gp140 proteins derived from the R5-tropic HIV-1 SF162 virus were analyzed and compared to the broadly reactive neutralizing antibody responses elicited during chronic infection of a macaque with a simian/human immunodeficiency virus (SHIV) expressing the HIV-1 SF162 Env, SHIV(SF162P4), and humans infected with heterologous HIV-1 isolates. Four gp140 immunogens were evaluated: SF162gp140, DeltaV2gp140 (lacking the crown of the V2 loop), DeltaV3gp140 (lacking the crown of the V3 loop), and DeltaV2DeltaV3gp140 (lacking both the V2 and V3 loop crowns). SF162gp140 and DeltaV2gp140 have been previously evaluated by our group in a pilot study, but here, a more comprehensive analysis of their immunogenic properties was performed. All four gp140 immunogens elicited stronger anti-gp120 than anti-gp41 antibodies and potent homologous neutralizing antibodies (NAbs) that primarily targeted the first hypervariable region (V1 loop) of gp120, although SF162gp140 also elicited anti-V3 NAbs. Heterologous NAbs were elicited by SF162gp140 and DeltaV2gp140 but were weak in potency and narrow in specificity. No heterologous NAbs were elicited by DeltaV3gp140 or DeltaV2DeltaV3gp140. In contrast, the SHIV(SF162P4)-infected macaque and HIV-infected humans generated similar titers of anti-gp120 and anti-gp41 antibodies and NAbs of significant breadth against primary HIV-1 isolates, which did not target the V1 loop. The difference in V1 loop immunogenicity between soluble gp140 and virion-associated gp160 Env proteins derived from SF162 may be the basis for the observed difference in the breadth of neutralization in sera from the immunized and infected animals studied here.
- Published
- 2006
- Full Text
- View/download PDF
33. Structural characteristics correlate with immune responses induced by HIV envelope glycoprotein vaccines.
- Author
-
Sharma VA, Kan E, Sun Y, Lian Y, Cisto J, Frasca V, Hilt S, Stamatatos L, Donnelly JJ, Ulmer JB, Barnett SW, and Srivastava IK
- Subjects
- Animals, Antibodies, Neutralizing immunology, Antibody Affinity, Binding Sites, CHO Cells, Cricetinae, HIV Antibodies immunology, HIV Infections immunology, HIV Infections prevention & control, Humans, Immunodominant Epitopes chemistry, Immunodominant Epitopes genetics, Immunodominant Epitopes immunology, Rabbits, Structure-Activity Relationship, env Gene Products, Human Immunodeficiency Virus genetics, AIDS Vaccines chemistry, AIDS Vaccines genetics, AIDS Vaccines immunology, CD4 Antigens chemistry, CD4 Antigens genetics, env Gene Products, Human Immunodeficiency Virus chemistry, env Gene Products, Human Immunodeficiency Virus immunology
- Abstract
HIV envelope glycoprotein (Env) is the target for inducing neutralizing antibodies. Env is present on the virus surface as a trimer, and, upon binding to CD4, a cascade of events leads to structural rearrangement exposing the co-receptor binding site and entry into the CD4+ host target cells. We have designed monomeric and trimeric Env constructs with and without deletion of the variable loop 2 (ΔV2) from SF162, a subtype B primary isolate, and performed biophysical, biochemical and immunological studies to establish a potential structure–functional relationship. We expressed these Envs in CHO cells, purified the proteins to homogeneity and performed biophysical studies to define the binding properties to CD4, structural characteristics and exposure of epitopes recognized by b12 and CD4i mAb (17B) on both full-length and mutant HIV Env proteins. Parameters evaluated include oligomerization state, number and affinity of CD4 binding sites, enthalpy and entropy of the Env–CD4 interaction and affinity for b12 and 17b mAbs. We observed one CD4 binding site per monomer and three active CD4 binding sites per trimer. A40-fold difference in affinity of the gp120 monomer vs. the o-gp140 trimer towards CD4 was observed (Kd = 58 nM and 1.5 nM, respectively),whereas only a 2-fold difference was observed for the V2 deleted Envs (Kd of gp120ΔV2 = 19 nM, Kd of o-gp140DV2 = 9.3 nM). Monomers had 3-fold higher affinity to the mAb 17b and at least 3-fold weaker affinity to b12 compared to trimers, with gp120DV2 having the weakest affinity for b12 (Kd = 446 nM). Affinity of CD4 binding correlated with proportion of the antibodies induced against the conformational epitopes by the corresponding Envs, and changes in mAb binding correlated with the induction of antibodies directed against linear epitopes. Furthermore,biophysical analysis reveals that the V2 deletion has broad structural implications in the monomer not shared by the trimer, and these changes are reflected in the quality of the immune responses induced in rabbits. These data suggest that biophysical characteristics of HIV Env, such as affinity for CD4, and exposure of important neutralizing epitopes, such as those recognized by b12 mAb, may be important predictors of its in vivo efficacy and may serve as important surrogate markers for screening Env structures as potential vaccine candidates., (©2006 Elsevier Inc. All rights reserved.)
- Published
- 2006
- Full Text
- View/download PDF
34. Immunization with HIV-1 SF162-derived Envelope gp140 proteins does not protect macaques from heterologous simian-human immunodeficiency virus SHIV89.6P infection.
- Author
-
Xu R, Srivastava IK, Kuller L, Zarkikh I, Kraft Z, Fagrouch Z, Letvin NL, Heeney JL, Barnett SW, and Stamatatos L
- Subjects
- AIDS Vaccines administration & dosage, Animals, CD4 Lymphocyte Count, Disease Models, Animal, Enzyme-Linked Immunosorbent Assay, Gene Products, env genetics, HIV Antibodies blood, HIV Infections immunology, HIV Infections virology, HIV-1 physiology, Interferon-gamma biosynthesis, Leukocytes, Mononuclear immunology, Macaca mulatta, Neutralization Tests, RNA, Viral blood, SAIDS Vaccines administration & dosage, Simian Acquired Immunodeficiency Syndrome immunology, Simian Acquired Immunodeficiency Syndrome virology, Simian Immunodeficiency Virus immunology, Vaccines, Subunit administration & dosage, Vaccines, Subunit immunology, Viral Load, env Gene Products, Human Immunodeficiency Virus, AIDS Vaccines immunology, Gene Products, env immunology, HIV Infections prevention & control, HIV-1 immunology, SAIDS Vaccines immunology, Simian Acquired Immunodeficiency Syndrome prevention & control
- Abstract
Immunization by the SF162gp140 or the DeltaV2gp140 HIV-1 envelope proteins results in the generation of strong homologous neutralizing antibodies (NAbs) that offer similar degree of protection from disease-development to macaques challenged with homologous virus. These two immunogens elicit weak cross-reactive NAbs and their effectiveness against heterologous challenge is currently unknown. To examine this issue, we immunized macaques with SIVGag p55 and either the SF162gp140 or the DeltaV2gp140 and challenged them intravenously with SHIV-89.6P. All animals became infected but previous immunization with SF162gp140 accelerated the development of anti-SHIV89.6P neutralizing antibody responses following infection. DeltaV2gp140 is derived from SF162gp140 following the deletion of 30 amino acids and one N-linked glycosylation site from the V2 loop. Our results suggest that even small differences in HIV Envelope immunogen structure can affect the neutralizing antibody responses generated following infection.
- Published
- 2006
- Full Text
- View/download PDF
35. Development of V2-deleted trimeric envelope vaccine candidates from human immunodeficiency virus type 1 (HIV-1) subtypes B and C.
- Author
-
Barnett SW, Srivastava IK, Ulmer JB, Donnelly JJ, and Rappuoli R
- Subjects
- AIDS Vaccines genetics, Animals, Clinical Trials, Phase I as Topic, Drug Evaluation, Preclinical, Enzyme-Linked Immunosorbent Assay, Gene Products, env chemistry, Gene Products, env genetics, HIV Infections prevention & control, HIV-1 classification, HIV-1 genetics, Humans, Neutralization Tests, Rabbits, Vaccines, DNA genetics, Vaccines, DNA immunology, Vaccines, Synthetic genetics, Vaccines, Synthetic immunology, env Gene Products, Human Immunodeficiency Virus, AIDS Vaccines immunology, Gene Products, env immunology, HIV Antibodies blood, HIV-1 immunology
- Abstract
The urgent need for a vaccine against HIV/AIDS requires that multiple strategies be employed and evaluated in a clinical setting. V2-loop deleted trimeric envelope (Env) immunogens (protein and DNA) from subtypes B and C human immunodeficiency virus type 1 (HIV-1) strains were produced for ongoing and future clinical evaluations with other HIV antigens, adjuvants and deliveries.
- Published
- 2005
- Full Text
- View/download PDF
36. Role of neutralizing antibodies in protective immunity against HIV.
- Author
-
Srivastava IK, Ulmer JB, and Barnett SW
- Subjects
- Animals, Antibody Specificity, Epitopes immunology, HIV Infections epidemiology, Humans, AIDS Vaccines immunology, HIV Antibodies immunology, HIV Infections immunology, HIV Infections prevention & control
- Abstract
HIV continues to be a major health problem world wide, however the situation is particularly serious in Asian and Sub-Saharan countries. Therefore, development of an effective HIV vaccine could help to reduce the severity of the disease and prevent infection. Over the last two decades significant efforts have been made towards inducing potent humoral and cellular immune responses by vaccination, however antibodies and CTL responses alone are likely not sufficient for inducing sterilizing immunity or long-term control of viral replication. Therefore, it is generally believed that both humoral and cellular responses will be needed for an effective HIV vaccine. In support of humoral immunity, monoclonal antibodies that recognize critical neutralizing epitopes have shown to be effective at passive transfer experiments in conferring protection against challenge infection. However, antibodies to similar epitope specificities are difficult to induce by vaccination. Therefore, optimization of Env structure is needed for exposing appropriate neutralizing epitopes and masking non-neutralizing epitopes. Since the crystal structure of the core of Env glycoprotein has been solved, efforts are in progress to design novel Env immunogens that may induce effective neutralizing responses. Furthermore, there are HIV-1 strains that are resistant to neutralization by monoclonal antibodies, yet neutralized by pooled sera from HIV-1 patients. Therefore, efforts should be made to identify these novel epitopes and to design strategies to incorporate them in potential vaccines. To facilitate comparative evaluation of vaccine immunogens for their ability to induce cross clade neutralizing antibodies, efforts should be made to use standardized neutralization assays and standard virus panels. Once potent HIV Env structure have been identified, their effectiveness may be enhanced through the use of adjuvants, delivery systems and prime and boost strategies to improve the quality and magnitude of neutralizing responses.
- Published
- 2005
- Full Text
- View/download PDF
37. Neutralizing antibody responses to HIV: role in protective immunity and challenges for vaccine design.
- Author
-
Srivastava IK, Ulmer JB, and Barnett SW
- Subjects
- Animals, HIV-1 immunology, Humans, AIDS Vaccines immunology, HIV Antibodies immunology, HIV Infections immunology, HIV Infections prevention & control
- Abstract
AIDS continues to be a major health problem throughout the world with a high degree of mortality and morbidity. Therefore, there is an urgent need for an effective anti-HIV vaccine. Although the correlates of protective immunity against infection by HIV remain unidentified, recent studies have demonstrated that both humoral and cellular responses are required for controlling viral replication. Vaccine efforts should therefore aim at developing broad and potent humoral as well as cellular responses. Anti-HIV T-cell responses can be generated both in animals and humans by several vaccine modalities. In contrast, broadly neutralizing antibody responses against HIV have not been elicited by any strategy tested in the clinic thus far. The presence of such responses has the potential to prevent the establishment of infection. If not, the presence of neutralizing antibodies may significantly reduce the number of cells that become infected, therefore reducing the inoculum, which may delay viral spread and allow for a better control of viral replication in the infected host. Finally, cytotoxic T-lymphocytes may facilitate the clearance of virally infected cells. One of the biggest challenges in HIV vaccine development is to design a HIV envelope immunogen that can induce protective neutralizing antibodies effective against the diverse HIV-1 strains that characterize the global pandemic. The focus of this article is to review the importance of antibodies and the strategies that are currently being used for inducing such antibodies.
- Published
- 2004
- Full Text
- View/download PDF
38. Immunogenicity of HIV-1 Env and Gag in baboons using a DNA prime/protein boost regimen.
- Author
-
Leung L, Srivastava IK, Kan E, Legg H, Sun Y, Greer C, Montefiori DC, zur Megede J, and Barnett SW
- Subjects
- Animals, Antibody Affinity, Cell Division immunology, DNA, Viral genetics, Female, Gene Products, env genetics, Gene Products, gag immunology, HIV Antibodies biosynthesis, HIV-1 genetics, Immunization methods, Immunization, Secondary methods, Mutagenesis, Insertional, Papio, T-Lymphocytes, Helper-Inducer immunology, env Gene Products, Human Immunodeficiency Virus, AIDS Vaccines immunology, Gene Products, env immunology, HIV-1 immunology, Vaccines, DNA immunology
- Abstract
Objectives: To evaluate the immunogenicity of sequence-modified HIV env and gag in baboons using DNA prime and protein boost strategy., Methods: Synthetic sequence-modified HIV gene cassettes were constructed that expressed three different forms of Env proteins, gp140, gp140mut and gp140TM, plus or minus a mutation in the protease-cleavage site. These plasmids were used to immunize baboons (Papio cynocephalus). A group of baboons was also immunized with both env and gag DNA followed by p55Gag virus-like particles (VLP) boost., Results: Modest antibody responses and low or no lymphoproliferative responses were observed following multiple DNA immunizations. In contrast, strong antibodies and substantial antigen-specific lymphoproliferative responses were seen following booster immunizations with oligomeric Env protein (o-gp140US4) in MF59. Neutralizing antibody responses were scored against T cell line adapted HIV-1 strains after the protein boosters, but neutralizing responses were low or absent against homologous and heterologous primary isolate strains. In the group receiving both gag and env vaccines, modest antigen-specific antibody and lymphoproliferative responses were scored after the DNA immunizations; these responses were enhanced several-fold upon boosting with the VLP preparations. The addition of Gag antigen did not interfere with Env-specific antibody responses, but there was a negative effect on the levels of Env-specific lymphoproliferation., Conclusions: These results highlight the importance of improving the potency of HIV DNA vaccines by enhanced DNA delivery and prime-boost vaccine technologies to generate more robust immune responses in larger animal models. In addition, care must be taken when immunizations with Env and Gag antigens are performed together.
- Published
- 2004
- Full Text
- View/download PDF
39. Purification, characterization, and immunogenicity of a soluble trimeric envelope protein containing a partial deletion of the V2 loop derived from SF162, an R5-tropic human immunodeficiency virus type 1 isolate.
- Author
-
Srivastava IK, Stamatatos L, Kan E, Vajdy M, Lian Y, Hilt S, Martin L, Vita C, Zhu P, Roux KH, Vojtech L, C Montefiori D, Donnelly J, Ulmer JB, and Barnett SW
- Subjects
- Amino Acid Sequence, Animals, CD4 Antigens metabolism, CHO Cells, Cricetinae, Gene Products, env chemistry, Gene Products, env immunology, Glycosylation, Humans, Macaca mulatta, Microscopy, Electron, Molecular Sequence Data, env Gene Products, Human Immunodeficiency Virus, Gene Products, env isolation & purification, HIV-1 chemistry
- Abstract
The envelope (Env) glycoprotein of human immunodeficiency virus type 1 (HIV-1) is the major target of neutralizing antibody responses and is likely to be a critical component of an effective vaccine against AIDS. Although monomeric HIV envelope subunit vaccines (gp120) have induced high-titer antibody responses and neutralizing antibodies against laboratory-adapted HIV-1 strains, they have failed to induce neutralizing antibodies against diverse heterologous primary HIV isolates. Most probably, the reason for this failure is that the antigenic structure(s) of these previously used immunogens does not mimic that of the functional HIV envelope, which is a trimer, and thus these immunogens do not elicit high titers of relevant functional antibodies. We recently reported that an Env glycoprotein immunogen (o-gp140SF162DeltaV2) containing a partial deletion in the second variable loop (V2) derived from the R5-tropic HIV-1 isolate SF162, when used in a DNA priming-protein boosting vaccine regimen in rhesus macaques, induced neutralizing antibodies against heterologous subtype B primary isolates as well as protection to the vaccinated animals upon challenge with pathogenic SHIV(SF162P4) virus. Here we describe the purification of this protein to homogeneity, its characterization as trimer, and its ability to induce primary isolate-neutralizing responses in rhesus macaques. Optimal mutations in the primary and secondary protease cleavage sites of the env gene were identified that resulted in the stable secretion of a trimeric Env glycoprotein in mammalian cell cultures. We determined the molecular mass and hydrodynamic radius (R(h)) using a triple detector analysis (TDA) system. The molecular mass of the oligomer was found to be 324 kDa, close to the expected M(w) of a HIV envelope trimer protein (330 kDa), and the hydrodynamic radius was 7.27 nm. Negative staining electron microscopy of o-gp140SF162DeltaV2 showed that it is a trimer with considerable structural flexibility and supported the data obtained by TDA. The structural integrity of the purified trimeric protein was also confirmed by determinations of its ability to bind the HIV receptor, CD4, and its ability to bind a panel of well-characterized neutralizing monoclonal antibodies. No deleterious effect of V2 loop deletion was observed on the structure and conformation of the protein, and several critical neutralization epitopes were preserved and well exposed on the purified o-gp140SF162DeltaV2 protein. In an intranasal priming and intramuscular boosting regimen, this protein induced high titers of functional antibodies, which neutralized the vaccine strain, i.e., SF162. These results highlight a potential role for the trimeric o-gp140SF162DeltaV2 Env immunogen in a successful HIV vaccine.
- Published
- 2003
- Full Text
- View/download PDF
40. Gene vaccines.
- Author
-
Srivastava IK and Liu MA
- Subjects
- Animals, Antibody Formation, Bacteria, Clinical Trials as Topic, Disease Models, Animal, Genetic Vectors, Humans, Infection Control, Neoplasms prevention & control, T-Lymphocytes, Cytotoxic physiology, T-Lymphocytes, Helper-Inducer physiology, Viruses, Vaccines, DNA adverse effects
- Abstract
Gene vaccines are a new approach to immunization and immunotherapy in which, rather than a live or inactivated organism (or a subunit thereof), one or more genes that encode proteins of the pathogen are delivered. The goal of this approach is to generate immunity against diseases for which traditional vaccines and treatments have not worked, to improve vaccines, and to treat chronic diseases. Gene vaccines make use of advances in immunology and molecular biology to more specifically tailor immune responses (cellular or humoral, or both) against selected antigens. They are still under development in research and clinical trials. The mechanisms for inducing cellular (as opposed to humoral) responses against a particular antigen have been elucidated. Gene vaccines provide a means to generate specific cellular responses while still generating antibodies, if desired. In addition, by delivering only the genes that encode the particular proteins against which a protective or therapeutic immune response is desired, the potential limitations and risks of certain other approaches can be avoided. This article describes the rationale for, immunologic mechanisms involved in, and design of gene vaccines under development. Preclinical and clinical studies of these vaccines are discussed for various clinical applications, focusing on infectious diseases.
- Published
- 2003
- Full Text
- View/download PDF
41. Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region.
- Author
-
Srivastava IK, VanDorsten K, Vojtech L, Barnett SW, and Stamatatos L
- Subjects
- Amino Acid Sequence, Animals, Cross Reactions, Gene Deletion, HIV Antibodies blood, HIV Antigens immunology, HIV Envelope Protein gp120 immunology, HIV Infections prevention & control, HIV-1 immunology, Humans, Immunization, Macaca mulatta, Molecular Sequence Data, Neutralization Tests, Peptides chemistry, Peptides immunology, Solubility, AIDS Vaccines immunology, Complementarity Determining Regions genetics, Gene Products, env immunology
- Abstract
Immunization of macaques with the soluble oligomeric gp140 form of the SF162 envelope (SF162gp140) or with an SF162gp140-derived construct lacking the central region of the V2 loop (DeltaV2gp140) results in the generation of high titers of antibodies capable of neutralizing the homologous human immunodeficiency virus type 1 (HIV-1), SF162 virus (Barnett et al. J. Virol. 75:5526-5540, 2001). However, the DeltaV2gp140 immunogen is more effective than the SF162gp140 immunogen in eliciting the generation of antibodies capable of neutralizing heterologous HIV-1 isolates. This indicates that deletion of the V2 loop alters the immunogenicity of the SF162gp140 protein. The present studies were aimed at identifying the envelope regions whose immunogenicity is altered following V2 loop deletion. We report that the antibodies elicited by the SF162gp140 immunogen recognize elements of the V1, V2, and V3 loops, the CD4-binding site, and the C1 and C2 regions on the homologous SF162 gp120. With the exception of the V1 and V2 loops, the same regions are recognized on heterologous gp120 proteins. Surprisingly, although a minority of the SF162gp140-elicited antibodies target the V3 loop on the homologous gp120, the majority of the antibodies elicited by this immunogen that are capable of binding to the heterologous gp120s tested recognize their V3 loops. Deletion of the V2 loop has two effects. First, it alters the immunogenicity of the V3 and V1 loops, and second, it renders the C5 region immunogenic. Although deletion of the V2 loop does not result in an increase in the immunogenicity of the CD4-binding site per se, the relative ratio of anti-CD4-binding site to anti-V3 loop antibodies that bind to the heterologous gp120s tested is higher in sera collected from the DeltaV2gp140-immunized animals than in the SF162gp140-immunized animals. Overall, our studies indicate that it is possible to alter the immunogenic structure of the HIV envelope by introducing specific modifications.
- Published
- 2003
- Full Text
- View/download PDF
42. Purification and characterization of oligomeric envelope glycoprotein from a primary R5 subtype B human immunodeficiency virus.
- Author
-
Srivastava IK, Stamatatos L, Legg H, Kan E, Fong A, Coates SR, Leung L, Wininger M, Donnelly JJ, Ulmer JB, and Barnett SW
- Subjects
- Animals, Antibody Affinity, CD4 Antigens metabolism, CHO Cells, Cricetinae, Dimerization, HIV-1 immunology, Humans, Neutralization Tests, Oligosaccharides analysis, Protein Conformation, Rabbits, AIDS Vaccines administration & dosage, AIDS Vaccines immunology, Gene Products, env chemistry, Gene Products, env immunology, Gene Products, env isolation & purification, HIV Antibodies blood, HIV-1 classification, Immunization
- Abstract
Human immunodeficiency virus (HIV) continues to be a major public health problem throughout the world, with high levels of mortality and morbidity associated with AIDS. Considerable efforts to develop an effective vaccine for HIV have been directed towards the generation of cellular, humoral, and mucosal immune responses. A major emphasis of our work has been toward the evaluation of oligomeric (o-gp140) forms of the HIV type 1 (HIV-1) envelope protein for their ability to induce neutralizing antibody responses. We have derived stable CHO cell lines expressing o-gp140 envelope protein from the primary non-syncytium-inducing (R5) subtype B strain HIV-1(US4). We have developed an efficient purification strategy to purify oligomers to near homogeneity. Using a combination of three detectors measuring intrinsic viscosity, light scattering, and refractive index, we calculated the molecular mass of the oligomer to be 474 kDa, consistent with either a trimer or a tetramer. The hydrodynamic radius (R(h)) of o-gp140 was determined to be 8.40 nm, compared with 5.07 nm for the monomer. The relatively smaller R(h) of the oligomer suggests that there are indeed differences between the foldings of o-gp140 and gp120. To assess the structural integrity of the purified trimers, we performed a detailed characterization of the glycosylation profile of o-gp140, its ability to bind soluble CD4, and also its ability to bind to a panel of monoclonal antibodies with known epitope specificities for the CD4 binding site, the CD4 inducible site, the V3 loop, and gp41. Immunogenicity studies with rabbits indicated that the purified o-gp140 protein was highly immunogenic and induced high-titer, high-avidity antibodies directed predominantly against conformational epitopes. These observations confirm the structural integrity of purified o-gp140 and its potential as a vaccine antigen.
- Published
- 2002
- Full Text
- View/download PDF
43. Resistance mutations reveal the atovaquone-binding domain of cytochrome b in malaria parasites.
- Author
-
Srivastava IK, Morrisey JM, Darrouzet E, Daldal F, and Vaidya AB
- Subjects
- Amino Acid Sequence, Animals, Atovaquone, Base Sequence, Chickens, Cytochrome b Group genetics, DNA, Mitochondrial genetics, Drug Resistance genetics, Electron Transport drug effects, Membrane Potentials drug effects, Methacrylates, Mice, Mice, Inbred BALB C, Mitochondria metabolism, Models, Molecular, Molecular Sequence Data, Naphthoquinones chemistry, Plasmodium yoelii pathogenicity, Sequence Analysis, DNA, Thiazoles pharmacology, Ubiquinone chemistry, Antimalarials pharmacology, Naphthoquinones pharmacology, Plasmodium yoelii genetics
- Abstract
Atovaquone represents a class of antimicrobial agents with a broad-spectrum activity against various parasitic infections, including malaria, toxoplasmosis and Pneumocystis pneumonia. In malaria parasites, atovaquone inhibits mitochondrial electron transport at the level of the cytochrome bc1 complex and collapses mitochondrial membrane potential. In addition, this drug is unique in being selectively toxic to parasite mitochondria without affecting the host mitochondrial functions. A better understanding of the structural basis for the selective toxicity of atovaquone could help in designing drugs against infections caused by mitochondria-containing parasites. To that end, we derived nine independent atovaquone-resistant malaria parasite lines by suboptimal treatment of mice infected with Plasmodium yoelii; these mutants exhibited resistance to atovaquone-mediated collapse of mitochondrial membrane potential as well as inhibition of electron transport. The mutants were also resistant to the synergistic effects of atovaquone/ proguanil combination. Sequencing of the mitochondrially encoded cytochrome b gene placed these mutants into four categories, three with single amino acid changes and one with two adjacent amino acid changes. Of the 12 nucleotide changes seen in the nine independently derived mutants 11 replaced A:T basepairs with G:C basepairs, possibly because of reactive oxygen species resulting from atovaquone treatment. Visualization of the resistance-conferring amino acid positions on the recently solved crystal structure of the vertebrate cytochrome bc1 complex revealed a discrete cavity in which subtle variations in hydrophobicity and volume of the amino acid side-chains may determine atovaquone-binding affinity, and thereby selective toxicity. These structural insights may prove useful in designing agents that selectively affect cytochrome bc1 functions in a wide range of eukaryotic pathogens.
- Published
- 1999
- Full Text
- View/download PDF
44. A mechanism for the synergistic antimalarial action of atovaquone and proguanil.
- Author
-
Srivastava IK and Vaidya AB
- Subjects
- Animals, Antimycin A analogs & derivatives, Antimycin A pharmacology, Atovaquone, Drug Synergism, Female, Folic Acid Antagonists pharmacology, Male, Membrane Potentials drug effects, Mice, Mice, Inbred BALB C, Mitochondria drug effects, Mitochondria metabolism, Oxygen Consumption drug effects, Plasmodium yoelii metabolism, Antimalarials pharmacology, Naphthoquinones pharmacology, Plasmodium yoelii drug effects, Proguanil pharmacology
- Abstract
A combination of atovaquone and proguanil has been found to be quite effective in treating malaria, with little evidence of the emergence of resistance when atovaquone was used as a single agent. We have examined possible mechanisms for the synergy between these two drugs. While proguanil by itself had no effect on electron transport or mitochondrial membrane potential (DeltaPsim), it significantly enhanced the ability of atovaquone to collapse DeltaPsim when used in combination. This enhancement was observed at pharmacologically achievable doses. Proguanil acted as a biguanide rather than as its metabolite cycloguanil (a parasite dihydrofolate reductase [DHFR] inhibitor) to enhance the atovaquone effect; another DHFR inhibitor, pyrimethamine, also had no enhancing effect. Proguanil-mediated enhancement was specific for atovaquone, since the effects of other mitochondrial electron transport inhibitors, such as myxothiazole and antimycin, were not altered by inclusion of proguanil. Surprisingly, proguanil did not enhance the ability of atovaquone to inhibit mitochondrial electron transport in malaria parasites. These results suggest that proguanil in its prodrug form acts in synergy with atovaquone by lowering the effective concentration at which atovaquone collapses DeltaPsim in malaria parasites. This could explain the paradoxical success of the atovaquone-proguanil combination even in regions where proguanil alone is ineffective due to resistance. The results also suggest that the atovaquone-proguanil combination may act as a site-specific uncoupler of parasite mitochondria in a selective manner.
- Published
- 1999
- Full Text
- View/download PDF
45. Atovaquone, a broad spectrum antiparasitic drug, collapses mitochondrial membrane potential in a malarial parasite.
- Author
-
Srivastava IK, Rottenberg H, and Vaidya AB
- Subjects
- Animals, Atovaquone, Erythrocytes drug effects, Erythrocytes parasitology, Erythrocytes physiology, Intracellular Membranes drug effects, Intracellular Membranes physiology, Mice, Mice, Inbred BALB C, Mitochondria physiology, Antimalarials pharmacology, Membrane Potentials drug effects, Mitochondria drug effects, Naphthoquinones pharmacology
- Abstract
At present, approaches to studying mitochondrial functions in malarial parasites are quite limited because of the technical difficulties in isolating functional mitochondria in sufficient quantity and purity. We have developed a flow cytometric assay as an alternate means to study mitochondrial functions in intact erythrocytes infected with Plasmodium yoelii, a rodent malaria parasite. By using a very low concentration (2 nM) of a lipophilic cationic fluorescent probe, 3,3'dihexyloxacarbocyanine iodide, we were able to measure mitochondrial membrane potential(DeltaPsim) in live intact parasitized erythrocytes through flow cytometry. The accumulation of the probe into parasite mitochondria was dependent on the presence of a membrane potential since inclusion of carbonyl cyanide m-chlorophenylhydrazone, a protonophore, dissipated the membrane potential and abolished the probe accumulation. We tested the effect of standard mitochondrial inhibitors such as myxothiazole, antimycin, cyanide and rotenone. All of them except rotenone collapsed the DeltaPsim and inhibited respiration. The assay was validated by comparing the EC50 of these compounds for inhibiting DeltaPsim and respiration. This assay was used to investigate the effect of various antimalarial drugs such as chloroquine, tetracycline and a broad spectrum antiparasitic drug atovaquone. We observed that only atovaquone collapsed DeltaPsim and inhibited parasite respiration within minutes after drug treatment. Furthermore, atovaquone had no effect on mammalian DeltaPsim. This suggests that atovaquone, shown to inhibit mitochondrial electron transport, also depolarizes malarial mitochondria with consequent cellular damage and death.
- Published
- 1997
- Full Text
- View/download PDF
46. Proteins with molecular masses of 25 to 40 kilodaltons elicit optimal protective responses against Plasmodium chabaudi adami infection.
- Author
-
Kima PE, Srivastava IK, and Long CA
- Subjects
- Animals, Antigens, Protozoan isolation & purification, Electrophoresis, Immunization, Male, Mice, Mice, Inbred BALB C, Molecular Weight, Protozoan Proteins isolation & purification, Antigens, Protozoan immunology, Malaria prevention & control, Plasmodium chabaudi immunology, Protozoan Proteins immunology
- Abstract
The presence of the CD4+ T cell has been shown to be crucial for resolution of acute infection in the Plasmodium chabaudi adami murine malaria model. This model is, therefore, suitable for the isolation of malaria antigens that are capable of activating protective T cells. In light of this, we set out to identify P. chabaudi adami molecules that activate protective responses in this model. Denatured P. chabaudi adami proteins were isolated by continuous-flow electrophoresis on the basis of their apparent molecular masses and then sequentially assessed for the ability to protect mice in immunization experiments. We report here that low-molecular-mass P. chabaudi adami polypeptides in the range from 25 to 40 kDa are most effective at immunizing mice against a challenge infection with viable P. chabaudi adami. The method used to obtain these proteins could also be applied to identify molecules that activate protective cell-mediated responses in other infectious disease models.
- Published
- 1992
- Full Text
- View/download PDF
47. Identification and purification of glucose phosphate isomerase of Plasmodium falciparum.
- Author
-
Srivastava IK, Schmidt M, Grall M, Certa U, Garcia AM, and Perrin LH
- Subjects
- Animals, Glucose-6-Phosphate Isomerase chemistry, Glucose-6-Phosphate Isomerase immunology, Isoelectric Focusing, Mice, Mice, Inbred BALB C, Glucose-6-Phosphate Isomerase isolation & purification, Plasmodium falciparum enzymology
- Abstract
The multiplication of malaria parasites within red blood cells is energy dependent. Since these parasites lack a functional tricarboxylic acid cycle, the energy needs of the parasite are met by anaerobic glycolysis of exogenous glucose. High levels of glycolytic enzymes such as fructose-1,6-diphosphate aldolase, phosphoglycerate kinase and pyruvate kinase have been detected in infected erythrocytes. Here we report a 4-9 times increase in glucose phosphate isomerase (GPI) activity of infected erythrocytes over that of normal erythrocytes. This increase is of parasitic origin, as additional enzyme bands were observed in lysates of infected erythrocytes. The expression of GPI parallels parasite maturation and reaches a maximum at the trophozoite/schizont stage. Two distinct but closely related activity patterns consisting of 3-4 GPI isoenzymes (not shown in normal erythrocytes) with neutral to weakly acidic isoelectric points were observed in 6 P. falciparum isolates tested by isoelectric focusing. The purified P. falciparum GPI has an apparent size of 66 kDa. No size variation was observed in the 6 P. falciparum isolates studied. Furthermore, antiserum raised against this protein in BALB/c mice specifically inhibits parasite encoded GPI activity while no effect was observed on host enzyme activity.
- Published
- 1992
- Full Text
- View/download PDF
48. Plasmodium falciparum: identification and purification of the phosphoglycerate kinase of the malaria parasite.
- Author
-
Grall M, Srivastava IK, Schmidt M, Garcia AM, Mauël J, and Perrin LH
- Subjects
- Animals, Blotting, Western, Chromatography, Ion Exchange, Erythrocytes parasitology, Humans, Immune Sera, Isoelectric Point, Kinetics, Mice, Mice, Inbred BALB C, Molecular Weight, Phosphoglycerate Kinase blood, Phosphoglycerate Kinase metabolism, Erythrocytes enzymology, Malaria, Falciparum enzymology, Phosphoglycerate Kinase isolation & purification, Plasmodium falciparum enzymology
- Abstract
Multiplication of the human malaria parasite Plasmodium falciparum within red blood cells is an energy-dependent process and glucose consumption increases dramatically in infected red blood cells (IRBC) versus normal red blood cells (NRBC). The major pathway for glucose metabolism in P. falciparum IRBC is anaerobic glycolysis. Phosphoglycerate kinase (PGK) is one of the key enzymes of this pathway as it generates ATP. We found that the PGK specific activity in P. falciparum IRBC is seven times higher than that in NRBC. The parasitic origin of the increase in PGK activity is confirmed by isoelectric focusing. Indeed, two P. falciparum isoenzymes with neutral isoelectric points were detected. P. falciparum PGK in purified form has a molecular mass of 48 kDa. Antiserum raised against purified P. falciparum PGK specifically recognizes the 48-kDa protein band in P. falciparum and also reacts with P. berghei and P. yoelii IRBC lysates but does not cross-react with PGK associated with NRBC.
- Published
- 1992
- Full Text
- View/download PDF
49. Comparative evaluation of an ELISA based on recombinant polypeptides and IFA for serology of malaria.
- Author
-
Srivastava IK, Schmidt M, Grall M, Yerly S, Garcia AM, Bouvier M, Takacs B, Dobeli H, and Perrin LH
- Subjects
- Adolescent, Adult, Animals, Antigens, Protozoan immunology, Child, Child, Preschool, Evaluation Studies as Topic, Humans, Malaria parasitology, Recombinant Proteins, Sensitivity and Specificity, Antibodies, Protozoan blood, Enzyme-Linked Immunosorbent Assay, Fluorescent Antibody Technique, Malaria immunology, Plasmodium falciparum immunology
- Abstract
In the present investigation we compare the performance of a solid-phase assay based on three recombinant polypeptides corresponding to three asexual blood-stage antigens of P. falciparum (ELISA MIXT) with the reference method for the measurement of antimalaria antibodies: indirect immunofluorescence antibody assay (IFA). Sera collected from persons with various degrees of exposure to malaria were selected: sera from inhabitants of a malaria endemic area (Group I), European patients with acute malaria infection (Group II) and blood donors with clinical symptoms of sickness or fever during a stay in malaria endemic areas. 86% of the sera gave concording results by ELISA MIXT and IFA. The correlation was 100% for sera of Group I but discrepancies were observed for Groups II and III. The great majority of the differences were due to sera positive on ELISA MIXT but not by IFA. Most of the sera positive on ELISA MIXT reacted with parasite-derived components only on Western-blot. These results underline the potential of the ELISA MIXT for epidemiologic studies.
- Published
- 1991
50. Expression, purification, biochemical characterization and inhibition of recombinant Plasmodium falciparum aldolase.
- Author
-
Döbeli H, Trzeciak A, Gillessen D, Matile H, Srivastava IK, Perrin LH, Jakob PE, and Certa U
- Subjects
- Amino Acid Sequence, Animals, Anion Exchange Protein 1, Erythrocyte metabolism, Cloning, Molecular, Fructose-Bisphosphate Aldolase antagonists & inhibitors, Fructose-Bisphosphate Aldolase genetics, Fructose-Bisphosphate Aldolase isolation & purification, Kinetics, Molecular Sequence Data, Protein Binding, Recombinant Proteins antagonists & inhibitors, Recombinant Proteins isolation & purification, Recombinant Proteins metabolism, Suramin pharmacology, Fructose-Bisphosphate Aldolase metabolism, Gene Expression, Plasmodium falciparum enzymology
- Abstract
The energy metabolism of the blood stage form of the human malaria parasite Plasmodium falciparum is adapted to the host cell. Like erythrocytes, P. falciparum merozoites lack a functional citric acid cycle. Generation of ATP depends therefore fully on the glycolytic pathway. Aldolase is a key enzyme of this pathway and a high degree of sequence diversity between parasite and host makes it a potential drug target. We have expressed the enzyme in its tetrameric form in Escherichia coli and the catalytic constants Vmax and Km of the recombinant enzyme correspond to the constants of parasite-derived aldolase. Rabbit antibodies against the recombinant P. falciparum aldolase inhibit the natural enzyme and no cross-reaction with human aldolase is detectable. Both the recombinant and the natural protein bind to the cytosolic domain of the band 3 membrane protein in vitro. A 19-residue synthetic peptide corresponding to the sequence of the binding domain of band 3 is an inhibitor when included in the binding assay. In addition, this peptide inhibits the catalytic activity of recombinant P. falciparum aldolase when assayed in a buffer system devoid of anions such as chloride or phosphate. The band 3-derived peptides compete with the aldolase substrate fructose-1,6-diphosphate for binding, suggesting that both reagents have a high affinity for the substrate pocket. A similar sequence motif exists in P. falciparum actin II. A 19-residue peptide corresponding to this sequence is also an inhibitor which could suggest that the P. falciparum aldolase can associate with the cytoskeleton of the parasite or of the host.
- Published
- 1990
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.